

PERSONAL INFORMATION



DELIA GOLETTI

[  
 Via Portuense 292,00152, Roma, Italy  
 +39-06-55170-906 +39-333-2896-394  
[delia.goletti@inmi.it](mailto:delia.goletti@inmi.it)  
[http://www.inmi.it/ricerca\\_traslazionale\\_english.html](http://www.inmi.it/ricerca_traslazionale_english.html)

Sex Female | Date of birth 18/05/1965 | Nationality Italian

WORK EXPERIENCE

From 06/1999 Head of Translational Research Unit, National Institute for Infectious Diseases (INMI), Rome Italy  
 Department of Epidemiology and Preclinical Research National Institute for Infectious Diseases  
 Via Portuense 292, Roma 00149, Italy

Consultant physician for the outpatient clinic at the Lung division of INMI

EDUCATION AND TRAINING

- 06/1999-09/2006 Clinical investigator, INMI, Roma, Italy (Scientific Director Dr Giuseppe Ippolito, MD). Physician for the inpatients clinic at the INMI in charge of patients with infectious diseases (HIV disease, tuberculosis, chronic and acute hepatitis, lung and neurological infections, sepsis, echinococcosis) (Director Dr Nicola Petrosillo). Head of the Translational Research Unit.
- 10/1996-05/1999: Staff scientist in the laboratory of Virology, Istituto Superiore di Sanità, (group directed by Dr Barbara Ensoli, MD, Ph.D), Roma, Italy
- 10/1996-10-1997: Resident in the Infectious Diseases Department, Catholic University of Roma, Italy (Head Professor Luigi Ortona, MD)
- 6/1996-9/1996: Visiting associate, Laboratory of Immunoregulation, (Chief: Anthony S. Fauci, M.D.), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, U.S.A.
- 10/1995: Doctorate in Infectious Diseases, Rome, Italy
- 10/1995-5/1996: Visiting fellow, Laboratory of Immunoregulation
- 10/92-9/95: Guest researcher, Laboratory of Immunoregulation
- 1990: Medical degree cum laude. Passed the examination of National Board in Italy
- 1984-1990: Medical student at the Catholic University of Rome

PERSONAL SKILLS

Mother tongue(s) Italian

|         | UNDERSTANDING |         | SPEAKING           |                   | WRITING |
|---------|---------------|---------|--------------------|-------------------|---------|
|         | Listening     | Reading | Spoken interaction | Spoken production |         |
| English | C2            | C2      | C2                 | C2                | C2      |
| French  | C1            | C1      | C1                 | C1                | C1      |
| Spanish | A1            | A1      | A1                 | A1                | A1      |

Professor at University Professor 06/A2-MED/02 in Medical Pathology at the UNICAMILLUS University, Faculty of Medicine

Publications

Presentations

Author of 215 publications as in PubMed  
She performed more than 200 presentations at national and international meetings

Honours and awards

- 2019 ▪ Top Italian Women Scientist
- 2016 ▪ FERS. The Fellow of the European Respiratory Society (ERS) title.
- 1996: ▪ Excellence in contributions to research, education and clinical leadership in respiratory medicine at ERS
- 1995: ▪ Fogarty fellowship from “ J. Fogarty Association”, Bethesda, Maryland
- 1993-1995: ▪ Fellowship for AIDS Research to be performed abroad funded by the Italian Ministry of Health
- 1990: ▪ Fellowship to perform the specialization in Infectious Diseases (first place)
- 1989: ▪ Fellowship to perform the Ph.D. program in Infectious diseases (first place)
- Fellowship to perform a Clinical Training in Switzerland funded by the “Committee for cultural interchange among the universities”

Memberships

- ERS, ESCMID, SIMIT

Citations

- Top Italian scientist list .Present in the list from 2014.  
[http://www.topitalianscientists.org/top\\_italian\\_scientists.aspx](http://www.topitalianscientists.org/top_italian_scientists.aspx)  
▪ **H index: 60 (Google Scholar); 52 (Scopus), 51 (Web of Science)**

Grants:

- 2020-2022:
  - BRIC: Studio degli aspetti organizzativi, immunologici e di genere per la prevenzione, diagnosi, sorveglianza e gestione dei rischi biologici occupazionali nel personale sanitario: un approccio integrato e personalizzato
- 2017-2018:
  - NIH project, subcontractor, “HLA-E restricted T-cell immunity in Mycobacterium tuberculosis infection
- 2017-2019:
  - PRIN , Progetto PRIN2015 20152CB22L “Ubiquitin E3 ligases as critical sensors in physiological and pathological conditions”
- 2014-2017:
  - TBVAC , EU funded project HORIZON2020, WP5 on TB biomarkers
- 2014-2017:
  - Role of IP-10 and its truncated form in the pathogenesis of tuberculosis, Italian Ministry of Health
- 2012-2014:
  - Genetic variability of Mycobacterium tuberculosis and its implications for transmission dynamics, pathogenesis and immune response, Italian Ministry of Health
- 2011-2008
  - IDEA (African-European Research Initiative on Co-infections of Poverty Related and Neglected Infectious Diseases), European Community
- 2010-2008:
  - New immune diagnostic tools to detect LTBI in HIV-infected subjects and evaluation of cART on the recovery of M. tuberculosis-specific response, Italian Ministry of Health
- 2010-2008:
  - Autophagy and tuberculosis, Italian Ministry of Health
- 2007-2008:
  - Immunodiagnostic test for MDR-tuberculosis, Italian Ministry of Health
- 2008-2007:
  - Comparison of commercial immune diagnostic tests and new immunodiagnostic test for tuberculosis in HIV+ subjects, Oxford Immunotec

Elected secretary or elected steering committee member of international societies or networks:

- ERS (European Respiratory Society), assembly 10.2 from 2012-2015, secretary
- ESCMID, European Society of Clinical Microbiology and Infectious Diseases, Mycobacteria group, ESGMYC Executive Committee, Secretary from April 2015. Chair from 2017.
- TBnet steering committee (responsible for the TB diagnostic area) from 2006-2012
- UNION, secretary of the European Region group, 2016-2018
- ERS, Advocacy TB Group, Secretary, 2016-2017
- Member of the Collaboration for TB Vaccine Discovery (CTVD) held by the Bill and Melinda Gates Foundation, since 2016.

Communication skills

Organisational / managerial skills

Excellent communication skills gained through years of activities with patients, fellows, co-workers, scientists. Capacity to interact at national and international level.

Job-related skills

Currently head for a team of 8 people, Coordinator of one national project for TB biomarkers (Ricerca Finalizzata), Principal Investigator head of several national and international projects on TB biomarkers, Chair of the Mycobacteria group at ESCMID.

Years of experience in delivering talks in national and international courses for tuberculosis on immune pathogenesis, immune diagnosis, clinical aspects, biomarkers. Clinical trials organization to evaluate TB biomarkers in India, Africa, Europe.

|  |  |
|--|--|
| Ad hoc reviewer  | <p>American Journal Of Critical Care Medicine, Archives of Medical Research, BMC Infectious Diseases, Cell Death and Differentiation, Clinical and Infectious Diseases, Clinical Experimental Immunology, Digestive and Liver Diseases, Diseases Markers, Drugs, E-bio, Emerging Infectious Diseases, European Respiratory Journal, European Journal of Clinical Microbiology &amp; Infectious Diseases, Expert Review of Molecular Diagnostics, Infection, International Journal of Antimicrobial Agents, International Journal of Infectious Diseases, Journal of Infections, Journal of Laboratory Clinical Medicine, Journal of Immunological Methods, Journal of Infection, Journal of Infectious Diseases, Journal of Infections and Public Health, Journal of Tuberculosis and Lung Diseases, Infectious Diseases, Lancet, Lancet Infectious Diseases, Lancet Respiratory Medicine, Molecular Diagnostics, Nature medicine, Nature communication, Open Journal of Infectious Diseases, PLoS Medicine, PLoS ONE, PLoS Pathogen, Plos Medicine, Respiratory Medicine, Reviews in Infections, Scandinavian Journal of Reumatology, Scandinavian Journal of Immunology, Scandinavian Journal of Infectious Diseases, The Lancet Respiratory Medicine, The Pediatric Journal Of Infectious Diseases, Trends in Microbiology, Tuberculosis, Tuberculosis Research and Treatment</p> |
| Participation to national and international meetings with WHO and ECDC | <p>Participation to the organization of the meeting on April 2-3, 2014 for the “Framework for tuberculosis elimination in low incidence countries – adaptation of the post-2015 global TB strategy”, organized by the WHO and ERS at Geneve, Switzerland</p> <p>Participation to the meeting ‘Framework Action Plan to Fight Tuberculosis in the European Union’ on April 28-29, 2014 and contributing to the gap analysis and defining options for filling the gaps organized by ECDC at Stockholm, Sweden</p> <p>Participation to the organization of the meeting on July 4-5, 2014 for the “Framework for tuberculosis elimination in low incidence countries – adaptation of the post-2015 global TB strategy”, organized by the WHO and ERS in Rome, Italy</p> <p>Participation to the launch of “Framework for tuberculosis elimination in low incidence countries – adaptation of the post-2015 global TB strategy”, at the ERS meeting in September 7th in Munich, Germany</p>   |
| Webinar  | <p>Management of TB infection in in HIV co-infected patients, Qiagen sponsored. Rome July 3<sup>rd</sup>, 2018</p>   |
| Co-chair of CTVD, Bill and Melinda Gates Foundation                    | <p>Conventional T cell community of the Collaboration for TB vaccine discovery (CTVD) which is an international network of scientists and experts dedicated to fostering innovation, cooperation, and collaboration in the up-stream TB vaccine discovery space. Supported by the Bill and Melinda Gates Foundation, Washington Seattle, USA. Cochair since 2018.</p>  |
| Advisory board consultant  | <p>Quidel, Biomerieux</p>  |
| International guidelines expert  | <p>ECIL (European conference on Infections in Leukemia)</p>  |

ANNEXES

---

### Invited Lectures/oral presentation to national and international meetings

1. SARS 2-Cov e Covid-19: strategie di un Virus e Strategie contro il Virus. European Womens Management Development «EWMD», Italia On AIR. Scenari di ripresa Post Covid: area Medica. June 11th, 2020
2. Gestione della malattie infettive nei pazienti in terapia con biologico, "Incontri reumatologici romani", February 22<sup>nd</sup>, 2020
3. Update on the research on TB biomarkers, TBVAC, Les Diablerets, Switzerland, January 27<sup>th</sup>, 2020
4. Echinococco e cibo: dobbiamo ancora avere paura? CONVEGNO ALIMENTAZIONE MULTIDISCIPLINARE in collaborazione con «Poster in Itinere» - patrocinato da OMCeO Roma, Casa Dell'Aviatore, Roma, 25 gennaio 2020
5. Revisione del protocollo di gestione clinica della tubercolosi. Revisione N. 8, INMI. Roma, December 10<sup>th</sup>, 2019
6. Screening della infezione tubercolare latente in persone con infezione da HIV, 18esimo congresso SIMIT, Palermo November 24<sup>th</sup>, 2019
7. Abbiamo bisogno di nuovi cut-off per la diagnosi di infezione tubercolare latente? 18esimo congresso SIMIT, Palermo 24 novembre 2019
8. Screening della infezione tubercolare e terapia preventiva, Modelli di gestione clinica per identificare il rischio di malattie infettive associato ai farmaci biologici, Corso INMI, November 7<sup>th</sup>, 2019
9. Overview sulla tubercolosi. Tubercolosi: Update and Prevention. Ospedale Bambino Gesù, Roma, 29 ottobre, 2019
10. La tubercolosi nel paziente anziano, 120 Congresso della Società Italiana di Medicina Interna (SIMI), October 20<sup>th</sup>, 2019
11. Understanding the use of interferon assays for latent tuberculosis infection diagnosis. Tuberculosis and Mycobacterial Infections; an educational update supported by ESCMID and WHO. Singapore, September 26<sup>th</sup>-28<sup>th</sup>, 2019
12. HIV-TB coinfection management. Tuberculosis and Mycobacterial Infections; an educational update supported by ESCMID and WHO. Singapore, September 26<sup>th</sup>-28<sup>th</sup>, 2019
13. Biomarkers for tuberculosis. Tuberculosis and Mycobacterial Infections; an educational update supported by ESCMID and WHO. Singapore, September 26<sup>th</sup>-28<sup>th</sup>, 2019
14. Gestione della tubercolosi nei pazienti trattati con farmaci biologici, Roma, 47 congresso nazionale SIM, Roma, September 19<sup>th</sup>, 2019
15. "How to test for latent tuberculosis infection", within the workshop of "TB Elimination in Low-Incidence Countries How to approach the pool of latent TB infections?", Muscat, Oman, September 5<sup>th</sup>, 2019
16. Prevenzione e terapia della tubercolosi, IBD&infections, Milano, June 28<sup>th</sup>, 2019
17. Can we really diagnose LTBI? 1st International Blizard/QMUL Tuberculosis Symposium, 26th & 27th June 2019, London June 26th, 2019
18. Conventional T cell group: activities. Seattle, USA, June 20th, 2019. 'Latent Tuberculosis Prevalence at HIV Diagnosis: a Multicenter SIMIT Study, ICAR 2019, Milano, 6 June, 2019
19. Echinococcosi cistica: aspetti epidemiologici e clinici, incontri inter-dipartimentali INMI, Roma 29 May, 2019
20. "It's time to test and treat latent TB infection", EUROMEDLAB, Barcelona, 22 May, 2019
21. "Innovative markers in the fight against tuberculosis", Tests for the future, Torino, 14-15 May, 2019
22. "Lo screening per la TB latente: è necessario per tutti i biologici? Auditorium della Camera di Commercio-Prato, evento scientifico. "La Reumatologia dal 1400 ai giorni nostri". Prato, 9 May, 2019
23. "Host-related markers of response to TB treatment", ESCMID, April 14th, 2019
24. "TB research at INMI", Bilateral Workshop on Transmissible Diseases: HIV/AIDS, Tuberculosis and Malaria Italy-South Africa Collaborative Workshop on the occasion of the Italian Research Day in the world, Pretoria, 5 April 2019
25. Confronto clinico con l'infettivologo, Congresso di Reumatologia della Campania: COMUNICARE OGGI, Napoli, 28 March, 2019
26. Il rischio di tubercolosi nella popolazione generale, TB day organizzato da STOP TB, Palermo, Palazzo dei Normanni, 21 March, 2019
27. Vaccini e farmaci biologici, Giornate reumatologiche romane, centro congressi AROMA, Roma 22 February, 2019
28. "Final update on TB biomarkers from the INMI team", presentation at the TBVAC, EU funded project, January 30th, 2019, Les Diableret, Switzerland.
29. Il trattamento dell'infezione latente nei pazienti candidati a farmaci biologici, XVII SIMIT, Torino, December 4th, 2018
30. LE MALATTIE BOLLOSE AUTOIMMUNI: DALLA GENESI ALLA CURA DEL PAZIENTE
31. Rischio infettivo in pazienti affetti da pemfigo e pemfigoide, LE MALATTIE BOLLOSE AUTOIMMUNI: DALLA GENESI ALLA CURA DEL PAZIENTE, Roma, December 1st, 2018
32. Biomarkers in tuberculosis, IV SYMPOSIUM ON RESEARCH, DEVELOPMENT AND INNOVATION IN BACTERIAL AND FUNGAL DISEASES, Improvements In Biomarkers, Host Interaction, and Life Quality", Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, November 22 - 23, 2018
33. Overview sui nuovi test per la diagnosi di infezione latente, XLVII AMCLI 2018, Rimini, 12 November, 2018
34. Impatto dei farmaci biologici anti-TNF sulla tubercolosi, epatiti e malattie opportunistiche, INMI, Impatto dei

- farmaci biologici sullo sviluppo delle malattie infettive, Roma 9 November 2018
35. Quantiferon-TB Gold Plus -an update on performance and comparing the 'new' with the 'old', UK TB Educational Symposium 2018, London, October 19<sup>th</sup>, 2018
  36. Il rischio tubercolare nella terapia con farmaci biologici, XXV riunione annuale, SIRS Puglia, October 5<sup>th</sup>, 2018
  37. Screening for Latent TB among Migrants in Italy, International Conference on Migration Health, Rome, October 2<sup>nd</sup>, 2018
  38. Biomarkers of latent tuberculosis infection and predictors of active disease, Management of Mycobacterial diseases and associated comorbidities, ESCMID course held in Rome, September 27-28, 2018
  39. Practical issues of the treatment of tuberculosis in immunocompromised patients (IRIS and drug Interactions). Management of Mycobacterial diseases and associated comorbidities, ESCMID course held in Rome, September 27-28, 2018
  40. TB biomarkers and studies on TB pathogenesis, University of Medicine, Southampton, September 14<sup>th</sup>, 2018.
  41. Infezione latente tubercolare, corso INMI, September, 25, 2018
  42. T cell based tests for cystic echinococcosis, Final meeting of the EU funded project Heracles, Istituto Superiore di Sanità, Rome, September 17<sup>th</sup>, 2018
  43. Management of TB infection in HIV co-infected patients, WEBINAR sponsored by QIAGEN, July 3<sup>rd</sup>, 2018
  44. Scelta del biologico in pazienti con tubercolosi latente, Prato, June 8<sup>th</sup>, 2018
  45. Il rischio infettivologico ed il trattamento con biologici, "Passato, Presente e Futuro delle ricerca sulla psoriasi", May 11, 2018
  46. La diagnosi della infezione tubercolare latente, Corso sulla diagnostica delle "Immagini della tubercolosi", INMI, Rome May 3, 2018.
  47. Issues in screening for latent tuberculosis, ECCMID, Madrid, April 21 2018,
  48. Rischio infettivo nel paziente con artrite psoriasica, Paziente 23, Workshop e Real life, Roma, 24 March, 2018
  49. Il test QuantiFERON Plus e la gestione diagnostica della infezione latente tubercolare, "La Tubercolosi e il test QuantiFERON: dal paziente nefropatico agli operatori sanitari", Napoli, 22 March, 2018
  50. Nouvelles études QuantiFERON®-TB Gold Plus, Infection Tuberculeuse Latente et IGRA: Etat des lieux en 2018, Institut Pasteur, Paris, 15 Mars, 2018
  51. Rischio infettivo nel paziente con artrite psoriasica, Paziente 23, Workshop e Real life, Milano 2 March, 2018
  52. "TB biomarkers: organization of the work at INMI", presentation at the TBVAC, EU funded project, January 30<sup>th</sup>, 2018, Les Diableret, Switzerland.
  53. "Biomarkers for diagnosis and treatment efficacy in tuberculosis", Fondation Merieux, Annecy, 14 December, 2017
  54. "Presentation of the multicenters study on the use of the in vitro response to HBHA as a tool to monitor therapy efficacy", Fondation Merieux, Annecy, 14 December, 2017
  55. "Nuovi potenziali test diagnostici per l'Echinococcosi", Aggiornamento sull'Echinococcosi: aspetti epidemiologici, clinici,diagnostici e terapeutici, INMI, 6 December, 2017.
  56. "Update on biomarkers for tuberculosis in HIV-TB coinfectd patients" All-Russian scientific practical conference with international participation «an interdisciplinary approach to solve the problem of tuberculosis», Moscow, 15 November, 2017
  57. "Update on biomarkers for tuberculosis" at the Federal State Budgetary Scientific Institution Central Tuberculosis Research Institute, Moscow, 13 November, 2017
  58. Diagnosi immunologica di echinococcosi cistica, CORSO SOIPA-SIM PER I GIOVANI MICROBIOLOGI su "La parassitologia, dalle basi alla pratica diagnostica. Micro-Young-Group: Advancement in Parasitology. Eboli, 25 October, 2017.
  59. "L'utilizzo di biomarcatori per predire lo sviluppo di TB attiva", Meeting INMI sull' "Appropriatezza nella presa in carico e nella gestione del paziente con TB-MDR. Roma, 24 October, 2017
  60. QuantiFERON TB Plus: nuova generazione di IGRA per la diagnosi di infezione tubercolare latente, Congresso SIMIT, Salerno, 17 October, 2017.
  61. Peptidi multiepitopici dell'antigene B per la diagnosi dell'echinococcosi cistica, Congresso SIMIT, Salerno, 17 October, 2017.
  62. Evaluation of the impact of M. tuberculosis on the autophagic flux. Kick-off meeting PRINN, Roma, July 7<sup>th</sup>, 2017
  63. Conventional T Cell Research Community report: CTVD Annual Meeting 2017, Bill and Melissa Gates Foundation, Washington Seattle, June 23, 2017
  64. "Diagnostica immunologica della tubercolosi: stato corrente e prospettive", University of Torvergata, Roma, May 23, 2017
  65. "Sospetto clinico e diagnosi di complicanza infettiva in pazienti trattati con terapia biologica", La gestione dei pazienti in terapia con farmaci biologici e small molecules: monitoraggio clinico e valutazioni farmaco-economiche, Prato 18-19 May, 2017.
  66. Evaluation of the autophagic flux as a potential biomarker for tuberculosis, 1st Joint WG4-WG5 TRANSAUTOPHAGY Translational Workshop, Lisbon, May 8, 2017
  67. "Recommendations for vaccine and testing immune response in tuberculosis", ECCMID, Vienna, 22 April, 2017



68. "Analytical evaluation of Quantiferon Plus and Quantiferon In-tube assays in subjects with or without tuberculosis", ECCMID, Vienna, 23 April, 2017
69. Gli IGRA: come posizionarli nell'algoritmo diagnostico?, Talk in "Update and new trends in respiratory Medicine", Sorrento 21 April, 2017
70. "Novità in tema di infezione tubercolare latente", Revisione del protocollo interno, National Institute for Infectious Diseases, Rome Italy, March 28th, 2017
71. "Prospettive dell'impiego di test immunologici per lo studio della tubercolosi latente", Word TB day 2017, National Institute for Infectious Diseases, Rome Italy, March 20th, 2017
72. "Characterization of the CD4 and CD8 T cell response in the QuantiFERON-TB-Plus kit", Second African Asian Society of Microbiology (AASM), Isfahan, Iran, February 26th, 2017
73. "TB biomarkers: organization of the work at INMI", presentation at the TBVAC, EU funded project, February 1st, 2017, Les Diableret, Switzerland.
74. "IGRA ed infezione tubercolare latente", INMI, Roma, November 24th, 2016
75. "Tubercolosi e Screening tra i Migranti", Ferrara November 18th, 2016
76. "Are there immunological tools for assessing TB cure?" PG course: Difficult to treat Mycobacterial infections. Organized by ECCMID, September 30th, 2016, Brac, Croatia
77. "Clinical aspects of TB, microbiological diagnosis of TB, HIV-TB and IRIS", elective course at the Medical School of Leiden, September 22nd, 2016, Medical School of Leiden, Netherland
78. "Research for tuberculosis biomarkers", Invited Seminar, September 23rd, 2016, University of Leiden, Netherland
79. "First experiences with QFT-Plus. Assessing performance and exploring CD8+ T-cell response". SEIMC, the Spanish Society of Infectious Diseases and Clinical Microbiology, May 28th, 2016, Barcelona, Spain.
80. "TB biomarkers: organization of the work at INMI", presentation at the TBVAC, EU funded project, February 3rd, 2016, Les Diableret, Switzerland.
81. "Assays to predict active tuberculosis development from latent tuberculosis infection", December 3rd, 2015, Union Meeting, Cape Town, South Africa
82. "Immune response to M. tuberculosis and search for new TB biomarkers", November 30th 2015, Cape Town University, Cape Town, South Africa
83. "Nuovi test IGRA: oltre il quantiFERON?", 13 november 2015, Università di Padova, Italy
84. "Toward an immune diagnostic test for CE diagnosis based on IL-4 specific response", 12 November 2015, Istituto Superiore di Sanità, Roma, Italy
85. "IGRA", 30 October, Istituto san Raffaele, Milan, Italy
86. "Algoritmo diagnostico dell'infezione tubercolare latente", October 27-28, 2015, INMI, Rome, Italy
87. "Evaluation of the accuracy of several immune experimental diagnostic tools to distinguish active tuberculosis from latent infection", European Respiratory Society Conference, 2015, Amsterdam, The Netherland.
88. "Quantiferon-TB Gold: criteri di interpretazione, accuratezza diagnostica, nuovi approcci diagnostici per la diagnosi di infezione tubercolare latente", 3rd July, 2015, Firenze, Italy.
89. Biologici e rischio infettivo: individualizzazione del rischio e scelta ragionata del biologico, 26 june, 2015, Prato, Italy.
90. Nuovi approcci diagnostici nell'infezione tubercolare, Università di Torvergata, June 23, 2015
91. "Migrants and infectious diseases", invited lecture at the Cystinet meeting, May 13th 2015, Rome, Italy
92. "CD27 expression as a new tool to distinguish active tuberculosis (TB) from latent TB infection", ECCMID 2015, April 26th, 2015, Copenhagen, Denmark
93. "Ruolo degli IGRA nella pratica clinica e nuovi test sperimentali per la diagnosi immunologica della tubercolosi", Ordine dei Medici di Roma, April 17th, 2015, Roma, Italy
94. "Immune response to *M. tuberculosis* and search for new biomarkers", University of Palermo, March 26th, 2015, Palermo, Italy
95. "TB biomarkers from diagnosis to protection", TB day celebration, INMI, Roma, March 23rd, 2015, Rome, Italy.
96. "TB biomarkers: organization of the work at INMI", presentation at the Kickoff meeting of TBVAC, EU funded project, February 12, 2015, Ijmuiden, The Netherland.
97. "Can blood or urine IP-10 discriminate between active and no active tuberculosis in children from high endemic areas?" Keystone meeting on Tuberculosis, January 26st, 2015, Rockville, MD, USA
98. "Immune response to *M. tuberculosis* and search of new TB biomarkers", AERAS, January 21st, 2015, Rockville,MD, USA
99. IGRA ed infezione tubercolare latente, Corso "Micobatteri e malattia tubercolare", INMI, Roma, November 26th, 2014, Rome, Italy.
100. Polyfunctional T cells and an effector memory phenotype are associated with active TB in HIV-infected patients, ERS meeting, September 9th, Munich, Germany, 2014
101. Identification and clinical management of LTBI in children versus adults, post graduate course at the ERS meeting (PG20 Global evaluation of tuberculosis from children to adults), September 6th, Munich, Germany, 2014

102. Polyfunctional T cells and an effector memory phenotype are associated with active TB in HIV-infected patients, 9th International Conference on the pathogenesis of Mycobacterial Infections, June 27<sup>th</sup>, 2014, Salsjobaden, Sweden.
103. Anti-TNF ed infezioni: il ruolo dei fattori di rischio correlati all'ospite, Artimino (Prato), June 6<sup>th</sup>, 2014
104. Diagnosi immunologica della tubercolosi: presente e futuro, Ospedale Pediatrico Bambino Gesù, TB day, 24 March, 2014, Rome, Italy
105. Immune diagnostic tests for tuberculosis: the present and the future, Department of Infectious Diseases, 13 February, 2014, San Gallen, Switzerland.
106. Nuovi approcci per la diagnosi immunologica della tubercolosi, Dipartimento di Malattie Infettive e Tropicali, Università di Pavia, 27 January, 2014, Pavia Italy.
107. Use of IGRAs in HIV-infected individuals in comparison to experimental tests, Pan European Symposium on the use of IGRA in HIV-infected individuals, 17 December, 2013, Paris, France.
108. Restitution of the boarding research committee of GABRIEL, 13 December, 2013, Annecy, France.
109. Rendicontazione progetto europeo IDEA , Dar Es Salam, Tanzania, 26 September 2013.
110. IP-10 urinario correla con la citolisi epatica nei pazienti con epatopatia HCV-correlata, Congresso SIMIT, 27-30 October, 2013, Milano, Italy.
111. IGRA ed infezione tubercolare latente, Sesto corso di Micobatteriologia avanzata, Milano 16-20 September, Ospedale San Raffaele, 2013 IFN- $\gamma$  Release Assays: advantages, limitations, new advances. Lecture. Annual congress of European Society of Mycobacteriology, July 3, 2013, Florence, Italy.
112. Infezione tubercolare latente: definizione, e nuovi approcci sperimentali diagnostici, Corso aziendale sulla tubercolosi, INMI, 27 June, 2013, Roma, Italy.
113. Sospetto clinico e diagnosi di tubercolosi attiva in pazienti trattati con farmaci biotecnologici, 7-8 June, 2013, Artimino (Prato), Italy.
114. Sensibilità e specificità del TST e IGRA per la diagnosi di infezione tubercolare latente, 7-8 June, 2013, Artimino (Prato), Italy.
115. Gestione del paziente con insorgenza di malattia tubercolare attiva durante il trattamento con farmaco biologico, 7-8 June, 2013, Artimino (Prato), Italy.
116. "Le Linee Guida Ministeriali 2013 sulla prevenzione della tubercolosi negli operatori sanitari", all'interno del meeting: "Il medico competente e la gestione del rischio TUBERCOLOSI in ospedale alla luce delle Linee Guida 2013 del Ministero della Salute" 15 May, 2013, Roma, Italy.
117. Corso annuale sulla "gestione della tubercolosi" organizzato dall'Università di Brescia, Diagnosi immunologica della tubercolosi e dell'infezione tubercolare latente: stato dell'arte e nuove prospettive, 15 April 2013, Sondalo, Italy.
118. Rendicontazione progetto europeo "Biomarkers for tuberculosis in urine", TB CHILD European grant 2010-2013, March 16<sup>th</sup>, 2013, Bagamoyo, Tanzania.
119. A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008), the 5<sup>th</sup> GABRIEL meeting, Les Pensières, December 10<sup>th</sup>, 2012, Annecy, France.
120. TB biomarkers and the role of autophagy in TB, Max Plank Institute, Berlin, Germany, November 15<sup>th</sup>, 2012
121. Tubercolosi: cross-road immigrato-viaggiatore, corso "Le Malattie Infettive del migrante e del viaggiatore, III edizione, 9 november 2012, Ferrara, Italy.
122. L'infezione tubercolare latente, corso "Tubercolosi: malattia riemergente, Percorsi clinici, diagnostici e terapeutici", 5 november, 2012, Lamezia Terme, Italy.
123. Il ruolo degli IGRA nella diagnosi di infezione tubercolare, SIMIT 2012, 20 October, 2012, Pescara, Italy.
124. Corso ECM, La diagnostica della tubercolosi, Presentazione su: Laboratorio, diagnostica immunologica, Istituto Nazionale per le Malattie Infettive L. Spallanzani, 11 October, 2012, Rome, Italy.
125. Corsi di Formazione ed aggiornamento professionale previsti dal programma di interventi urgenti per la prevenzione e la lotta contro l'AIDS (legge 135/1990), corso per il comparto dell'INMI, "Gestione dei contatti di caso", May, 2012, Rome, Italy.
126. What are the optimal approaches to discover correlates of protective immunity to tuberculosis? Emory Conference Center, April 14<sup>th</sup>, 2012, Atlanta, Georgia, USA.
127. Corsi di Formazione ed aggiornamento professionale previsti dal programma di interventi urgenti per la prevenzione e la lotta contro l'AIDS (legge 135/1990), corso per Medici della Regione Lazio, February 27<sup>th</sup>-28<sup>th</sup>, 2012, Rome, Italy.
128. Approaches on tuberculosis for developing countries, 4<sup>th</sup> international meeting. Report on the studies conducted by the GABRIEL network, Fondation Merieux, December, 5<sup>th</sup> 2011, Bamako, Mali.
129. Infezione tubercolare latente: definizione, diagnosi e indicazioni alla profilassi secondo le linee guida. Attualità in tema di diagnosi, clinica e profilassi della tubercolosi, Confederazione ANTEL-ASSIATEL-AITIC, Sede provinciale della Croce Rossa a Villa Marelli, November 26<sup>th</sup>, 2011, Rome, Italy.
130. Diagnosi immunologica della tubercolosi e dell'infezione tubercolare latente: stato dell'arte e nuove prospettive. Congresso AMCLI, invited lecture, November 10<sup>th</sup>, 2011, Rimini, Italy.

131. Diagnosi e profilassi dell'infezione tubercolare latente in ambito occupazionale, Università di Tor Vergata, Istituto di Medicina del Lavoro, October 21<sup>st</sup>, 2011, Rome, Italy.
132. Methylated HBHA produced in *M. smegmatis* discriminates between active and non-active TB disease among the QFT-IT-responders, ERS meeting, September 26<sup>th</sup>, 2011, Amsterdam, The Netherland.
133. Autophagy modulation by *Mycobacterium tuberculosis* after in vitro infection of human primary macrophages, Eight International conference on the pathogenesis of Mycobacterial Infection, July 2<sup>nd</sup>, 2011, Saltjobaden, Sweden.
134. Immunodiagnosis of tuberculosis, CHUV, June 15<sup>th</sup>, 2011, Losanne, Suisse.
135. La diagnosi di infezione e malattia tubercolare: stato dell'arte e nuove prospettive, TB day, Università Cattolica del Sacro Cuore, March 24<sup>th</sup>, 2011, Rome, Italy.
136. La diagnosi di tubercolosi polmonare latente. I test tubercolinici: utilità e limiti. Corso di aggiornamento teorico-pratico: la malattia tubercolare: attualità e prospettive diagnostiche e terapeutiche. February 19<sup>th</sup>, 2011, Crotona, Italy.
137. Approaches on tuberculosis for developing countries, December 16<sup>th</sup>, 2010, Veyrier du Lac, France.
138. La diagnosi di infezione e malattia tubercolare: oltre gli IGRA, Congresso della Società Italiana di Malattie Infettive e Tropicali, Hotel Ergife, 25 november, 2010, Rome, Italy.
139. Diagnosi immunologica della tubercolosi: stato dell'arte e nuove prospettive, Riccione, Palazzo dei Congressi, Congresso della Società Italiana di Microbiologia, 18 October 2010, Rome, Italy.
140. Come migliorare gli IGRA? Valutazioni di nuovi approcci sperimentali, Meeting di costituzione della rete romana per la tubercolosi, INMI, 6 September, 2010, Rome, Italy.
141. In HIV<sup>+</sup> subjects IP-10 is a marker for *M. tuberculosis*-specific response independent of CD4<sup>+</sup> T cell counts, ERS meeting, September 21<sup>st</sup>, 2010, Barcelona, Spain.
142. Biomarkers for tuberculosis in urine, 4<sup>th</sup> TBNET meeting, September 17<sup>th</sup>, 2010, Barcelona, Spain.
143. Tuberculosis in immunocompromised patients, "Tuberculosis in HIV-infected patients", Congress of the Romanian Society of Pulmonology, June 10-12, 2010, Bucharest, Romania.
144. Immunodiagnosis of Tuberculosis, ERS School Course on Tuberculosis at times of emerging drug resistance, May 27-29, 2010, Borstel, Germany.
145. Constrains and common mistakes in TB/MDR-TB clinical trials, ERS School Course on Tuberculosis at times of emerging drug resistance, May 27-29, 2010, Borstel, Germany.
146. Identification of antigens and antibodies in body fluids, Commemoration for the TB day, March 25<sup>th</sup>, 2010, Münchenwiler, Suisse.
147. Impact of Heminthiasis in HIV and TB diseases, Kick-off meeting of the European project IDEA, March 20-21, 2010, Amsterdam, the Netherland.
148. Experimental immune assays for the diagnosis of latent tuberculosis infection and active disease, University of Torvergata, Biology Department, February 19<sup>th</sup>, 2010, Roma, Italy.
149. LTBI treatment in subjects with autoimmune diseases and T-cell IFN- $\gamma$  responses, ERS 2009, September 15<sup>th</sup>, 2009, Vienna, Austria.
150. New tools to discriminate active from past tuberculosis: comparison of the response to RD1 antigens vs latency antigens, ERS 2009, September 15<sup>th</sup>, 2009, Vienna, Austria.
151. New tools to discriminate active tuberculosis disease from latent tuberculosis infection, May 30<sup>th</sup>, 2009, Dubrovnik, Croatia.
152. Immune diagnosis of active tuberculosis and latent tuberculosis infection, Corso di Perfezionamento TB; aspetti clinici, diagnostici, terapeutici on March 17<sup>th</sup>, 2009, Brescia, Italy.
153. Specificities of tuberculosis in HIV disease, organized by Merieueux Fondation, held as " Les Cent Gardes" meeting, March 4<sup>th</sup>, 2009, Delhi, India.
154. Tuberculosis in Children, Department of Pediatrics, Medical College, Agra, India, invited by Department of Pediatrics, Medical College, March 3<sup>rd</sup>, 2009, Agra, India.
155. Report on the activity to the evaluation on a test for the discrimination of active TB from LTBI based on the RD1 selected peptides, organized by Merieueux Fondation, December 2<sup>nd</sup>, 2008, New Delhi, India.
156. Symposium lecture, RD1-selected peptides for the immunodiagnosis of active tuberculosis, ERS meeting, October 6<sup>th</sup>, 2008, Berlin, Germany.
157. Post-graduate course: Future developments for the diagnosis *M. tuberculosis*-infection", ERS meeting, October 4<sup>th</sup>, 2008, Berlin, Germany.
158. An assay based on RD1 selected peptides for the diagnosis of extra-pulmonary and smear negative tuberculosis, ERS meeting, October 8<sup>th</sup>, 2008, Berlin, Germany.
159. Use of QuantiFERON TB Gold In Tube to detect LTBI and to monitor prophylaxis in children recently exposed to *M. tuberculosis*, ERS meeting, October 7<sup>th</sup>, 2008, Berlin, Germany.
160. Memory response to RD1 antigens in TST+ subjects: a better tool to detect LTBI?, ERS meeting, October 7<sup>th</sup>, 2008, Berlin, Germany.
161. Test per discriminare l'infezione latente tubercolare dalla malattia tubercolosi attiva, invited by Istituto di Patologia Generale, Università Facoltà di Medicina, June 16<sup>th</sup>, 2008, Palermo, Italy.



162. An assay based on RD1 selected peptides for the diagnosis of extra-pulmonary and smear negative tuberculosis, ATS 2008, May 18<sup>th</sup>, 2008, Toronto, Canada.
163. RD1-selected peptides for the immunodiagnosis of active tuberculosis: results from a multicenter TB-NET study, National Pneumology Congress, April 10<sup>th</sup>, 2008, Lubeck, Germany.
164. RD1-epitopes response for the immune diagnosis of tuberculosis, National Microbiologic Congress, April 6<sup>th</sup>, 2008, Plovdiv, Bulgaria.
165. Commemoration for Fabrizio Poccia, TB-VAC meeting, January 29<sup>th</sup>, 2008, Les Diablerets, Suisse.
166. RD1-epitopes response correlates with the time since first exposure in close contacts recently exposed to *M. tuberculosis*. European Respiratory Society, September 13<sup>th</sup>-14<sup>th</sup>, 2007, Stockholm, Sweden.
167. Response to RD1-selected epitopes is associated to active tuberculosis. Results of a european multicenter hospital based study: interim analysis of a european tuberculosis network (TBnet) study. European Respiratory Society, September 13<sup>th</sup>-14<sup>th</sup>, 2007, Stockholm, Sweden.
168. The clinical management of tuberculosis in HIV-coinfection, 17th ERS Annual Congress. European Respiratory Society, September 13<sup>th</sup>-14<sup>th</sup>, 2007, Stockholm, Sweden.
169. Priorities of Tuberculosis Research, Second annual meeting of the TBNET, September 13<sup>th</sup>-14<sup>th</sup>, 2007, Stockholm, Sweden.
170. Response to RD1-selected epitopes is associated to active tuberculosis. Results of a european multicenter hospital based study: interim analysis of a european tuberculosis network (TBnet) study. Second annual meeting of the TBNET, September 13<sup>th</sup>-14<sup>th</sup>, 2007, Stockholm, Sweden.
171. Immune diagnostic assays for the diagnosis of active tuberculosis and latent infection. National Annual Meeting of the Japanese Union against Tuberculosis. June 4<sup>th</sup>, 2007. Osaka, Japan.
- 172.** Immune diagnostic assays for the diagnosis of latent tuberculosis infection and active disease, Research Center October 2<sup>nd</sup>, 2007, Borstel, Germany.
173. Diagnosi immunologica della tubercolosi, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, 20 november 2006, Rome, Italy.
174. The role of a new immune diagnostic assay based on RD1 selected peptides in the evaluation of subjects with active *M. tuberculosis* replication. Tuberculosis Research Center (TBRC), October 30<sup>th</sup>, 2006, Chennai, India.
175. The role of a new immune diagnostic assay based on RD1 selected peptides in the evaluation of subjects with active *M. tuberculosis* replication. Department of Microbiology, Hinduja Hospital, November 2<sup>nd</sup>, 2006, Mumbai, India.
176. Response to ESAT-6/CFP-10 selected peptides response in the course of prophylaxis in individuals exposed to *M. tuberculosis*. ERS meeting, September 14<sup>th</sup>, 2006, Munich, Germany.
177. Dynamics of ESAT-6/CFP-10 selected peptides response in the course of prophylaxis in individuals exposed to *M. tuberculosis*. ATS meeting, May 22<sup>th</sup>, 2006, San Diego, USA.
178. The role of a new immune diagnostic assay based on RD1 selected peptides in the evaluation of subjects with active *M. tuberculosis* replication. Department of Microbiology and Immunology, Georgetown University, May 19<sup>th</sup>, 2006, Washington DC, USA.
179. A new diagnostic immune assay for tuberculosis diagnosis. Clinical evaluation of tool box for tuberculosis diagnosis, Foundation Mérieux and Indian Council of Medical Research. Delhi (India), December 22<sup>th</sup>, 2005.
180. Detection of *M. tuberculosis* transrenal DNA from urine samples of patients with pulmonary TB: proof of concept study. IUTLD. October 18-22, 2005, Paris, France.
181. Comparison of an assay based on RD1 selected peptides with commercially available assays based on RD1 overlapping peptides to identify subjects with active TB. 15th ERS Annual Congress. September 17<sup>th</sup>-21<sup>st</sup>, 2005, Copenhagen, Denmark.
182. A T-cell-based assay for rapid diagnosis of difficult cases of tuberculosis (TB): smear negative pulmonary and extra-pulmonary TB. 15th ERS Annual Congress. September 17-21<sup>th</sup>, 2005, Copenhagen, Denmark.
183. Immune diagnosis of tuberculosis. Case Western Reserve University, May 25<sup>th</sup>, 2005, Cleveland, Ohio, USA.
184. Comparison of ELISPOT and whole blood assay for IFN-gamma in the immune diagnostic of tuberculosis using ESAT-6 and CFP-10 selected peptides, 14<sup>th</sup> ERS congress, September 4<sup>th</sup>-8<sup>th</sup>, 2004, Glasgow, UK.
185. Use of immunological assays based on selected ESAT-6 e CFP-10 peptides in the diagnosis of active TB, GISTA meeting, INMI, May 21<sup>st</sup>, 2004, Roma, Italy.
186. Immuno-diagnosis of active and latent tuberculosis, Department of Parasitology and immuno-mediated diseases, Istituto Superiore di Sanità, May 12<sup>st</sup>, 2004, Rome, Italy.
187. Clinical presentation and outcome of HIV-associated tuberculosis in the HAART era in Rome, 14<sup>th</sup> ECCMID congress, ECCMID, May 1<sup>st</sup> -4<sup>th</sup>, 2004, Prague, Czech Republic.
188. The role of new immune diagnostic test based on ESAT-6 epitopes in the evaluation of subjects with a clinical suspicion of active tuberculosis, 14<sup>th</sup> ECCMID congress, ECCMID, May 1<sup>st</sup> -4<sup>th</sup>, 2004, Prague, Czech Republic.
189. Immune diagnosis of tuberculosis. TB-VAC meeting, 6<sup>th</sup> Framework Programme, February 19<sup>st</sup> -20<sup>st</sup>, 2004, Leiden, The Netherland.

190. Immuno-diagnosis of tuberculosis, Division of Preventive Medicine, Azienda Sanitaria Locale San Camillo-Forlanini, March 10<sup>st</sup>, 2004, Viterbo, Italy.
191. Clinical-diagnostic issues of tuberculosis in patients with immuno-deficiencies, Giornate pneumologiche laziali, AIPO, sezione laziale, December 11<sup>th</sup>, 2003, Rome, Italy.
192. Identification of ESAT-6 epitopes for the development of an immunodiagnostic assay for the diagnosis of active and latent tuberculosis, Division of Infectious Diseases, Ospedale del Bambino Gesù, October 7<sup>th</sup>, 2003, Rome, Italy.
193. The role of new immune diagnostic test based on ESAT-6 epitopes in the screening of subjects with a clinical suspicion of active tuberculosis. 13<sup>st</sup> ERS congress, ERS, Vienna, Austria, September 27<sup>th</sup> -October 1<sup>st</sup>, 2003
194. Immuno-diagnosis of tuberculosis, Division of Infectious Diseases, Ospedale Belcolle, March 7<sup>th</sup>, Viterbo, Italy.
195. Identification of ESAT-6 epitopes for the development of an immunodiagnostic assay for the diagnosis of active and latent tuberculosis, INMI meeting with the Laboratory of Allergy and Infectious diseases of University "La Sapienza", October 10<sup>th</sup>, 2002, Rome, Italy.
196. Evaluation of cell population of the immune system susceptible to HHV-8 infection. Annual Congress of Istituto di Virologia, Istituto Superiore di Sanità, May 12, 1997, Roma, Italy.
197. Effect of tuberculosis in the pathogenesis of HIV infection, DIBIT, Istituto San Raffaele, April 14<sup>th</sup>, 1997, Milano, Italy.
198. Role of tuberculosis in the pathogenesis of HIV disease, Istituto di Patologia Generale, Università La Sapienza di Roma, February 11<sup>th</sup>, 1997, Roma, Italy.
199. Role of anti-inflammatory cytokines and chemokines in the modulation of tuberculosis-induced HIV replication, Department of Health and Human Services, USA, September 25<sup>th</sup>, 1996, Washington D.C., USA.
200. Effect of tuberculosis in the pathogenesis of HIV infection, Johns Hopkins University, School of Hygiene and Public Health, department of Molecular Microbiology and Immunology, September 19<sup>th</sup>, 1996, Baltimore, Maryland, USA.
201. Impact of opportunistic infections in the pathogenesis of HIV infection, Washington D.C. General Hospital, Tuberculosis and Chest Clinic, July 11<sup>th</sup>, 1996, Washington D.C., USA.
202. Role of immune activation in tuberculosis-induced HIV replication, Institute de Recherche de Montreal, Institute d'Immunologie, July 14<sup>th</sup>, 1996, Montreal, Canada.
203. Role of tuberculosis in the pathogenesis of HIV infection, 3<sup>th</sup> National Meeting on AIDS, January 29<sup>th</sup>-3<sup>st</sup> February, 1996, Washington, USA.
204. Role of tuberculosis in HIV infection, 9<sup>th</sup> International Congress in Immunology, July 23<sup>rd</sup>-29<sup>th</sup>, 1995, San Francisco, USA.
205. Expression of LFA-1 antigen in AIDS patients. 5<sup>th</sup> National Meeting on AIDS, 1991, Cagliari, Italy.

## **Bibliography:**

Catherine Wei Min Ong Giovanni Battista Migliori, Mario Raviglione, Gavin MacGregor-Skinner, Giovanni Sotgiu, Jan-Willem Alffenaar, Simon Tiberi, Cornelia Adlhoeh, Tonino Alonzi, Sophia Archuleta, Sergio Brusin, Emmanuelle Cambau, Maria Rosaria Capobianchi, Concetta Castilletti, Rosella Centis, Daniela M. Cirillo, Lia D'Ambrosio, Masoud Dara, Giovanni Delogu, Susanna M.R. Esposito, Jose Figueroa, Jon S. Friedland, Benjamin Ho Choon Heng, Giuseppe Ippolito, Tauhidul Islam A.B.M, Mateja Jankovic, Hannah Yejin Kim, Senia Rosales Klintz, Csaba Ködmön, Eleonora Lalle, Yee Sin Leo, Chi-Chiu Leung, Anne-Grete Märtson, Mario Melazzini, Saeid Najafi Fard, Pasi Penttinen, Linda Petrone, Elisa Petruccioli, Emanuele Pontali, Laura Saderi, Miguel Santin, Antonio Spanevello, Reinout van Crevel, Martin van den Boom, Marieke J. van der Werf, Dina Visca, Miguel Viveiros, Jean Pierre Zellweger, Alimuddin Zumla, **Delia Goletti**. Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members# of ESCMID Study Group for Mycobacterial Infections (ESGMYC). ERJ, in press.

Buonsenso D, Iodice F, Sorba J, Biala M, **Goletti D**. COVID-19 effects on Tuberculosis care in Sierra Leone, *Pulmonology*, in press, PII: S2531-0437(20)30130-6. DOI: <https://doi.org/doi:10.1016/j.pulmoe.2020.05.013>

Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M, Zumla A, Capobianchi MR, Lauria FN, Ippolito G. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. *J Transl Med*. 2020 Jun 10;18(1):233. doi: 10.1186/s12967-020-02405-w. PubMed PMID: 32522207.

Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, De Souza-Galvão ML, Dominguez-Castellano A, Dourmane S, Jachym MF, Froissart A, Giacomet V, **Goletti D**, Grard S, Gualano G, Izadifar A, Le Du D, Royo MM, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Rossato Silva D, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Taberner E, Tambyah PA, Tiberi S, Torre A, Visca D, Murguiondo MZ, Sotgiu G, Migliori GB. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J*. 2020 May 26;. doi: 10.1183/13993003.01398-2020.

Motta I, Centis R, D'Ambrosio L, García-García JM, **Goletti D**, Gualano G, Lipani F, Palmieri F, Sánchez-Montalvá A, Pontali E, Sotgiu G, Spanevello A, Stochino C, Taberner E, Tadolini M, van den Boom M, Villa S, Visca D, Migliori GB. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. *Pulmonology*. 2020 May 14;. doi: 10.1016/j.pulmoe.2020.05.002. [Epub ahead of print] PubMed PMID: 32411943; PubMed Central PMCID: PMC7221402.

Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, **Goletti D**. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J Infect*. 2020 May;80(5):536-546. doi: 10.1016/j.jinf.2020.02.009. Epub 2020 Feb 22. PubMed PMID: 32097688.

Lubbers R, Sutherland JS, **Goletti D**, de Paus RA, Dijkstra DJ, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Malherbe ST, Walz G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA. Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. *Mol Immunol*. 2020 Apr;120:187-195. doi: 10.1016/j.molimm.2020.02.006. Epub 2020 Mar 13. PubMed PMID: 32179338.

Esmail H, Cobelens F, **Goletti D**. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. *Eur Respir J*. 2020 Mar;55(3). doi: 10.1183/13993003.01957-2019. Print 2020 Mar. PubMed PMID: 31949119; PubMed Central PMCID: PMC7057180.

Tiberi S, Migliori GB, Muhwa Chakaya J, Kaesava T, Salem Al Abri S, Wejse C, **Goletti D**, Kapata N, Sotgiu G, Bomanji J, Zellweger JP, Hasan R, Irfan M, Ahmed I, Pshenichnaya N, Vasilieva I, Yeboah-Manu D, Alffenaar JW, Yeijin Kim H, Centis R, Cirillo DM, Alagna R, D'Ambrosio L, Maeurer M, Cui X, Cao B, Harries AD, Abri SA, Raviglione M, Zumla A, Petersen E, Ippolito G. Cover Editorial- IJID World TB Day 2020 Theme Series. *Int J Infect Dis*. 2020 Mar 4. pii: S1201-9712(20)30120-X. doi: 10.1016/j.ijid.2020.03.001.

Al Abri S, Kasaeva T, Migliori GB, **Goletti D**, Zenner D, Denholm J, Al Maani A, Cirillo DM, Schön T, Lillebæk T, Al-Jardani A, Go UY, Dias HM, Tiberi S, Al Yaquobi F, Khamis FA, Kurup P, Wilson M, Memish Z, Al Maqbali A, Akhtar M, Wejse C, Petersen E. Tools to implement the WHO End TB Strategy: Addressing common challenges in high and low endemic countries. *Int J Infect Dis*. 2020 Feb 27.

Petruccioli E, Chiacchio T, Navarra A, Vanini V, Cuzzi G, Cimaglia C, Codecasa LR, Pinnetti C, Riccardi N, Palmieri F, Antinori A, **Goletti D**. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. *J Infect*. 2020 Feb 22.

Palucci I, Maulucci G, De Maio F, Sali M, Romagnoli A, Petrone L, Fimia GM, Sanguinetti M, **Goletti D**, De Spirito M, Piacentini M, Delogu G. Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis. *Front Immunol*. 2020 Jan 24;10:3042.

Esmail H, Cobelens F, **Goletti D**. Transcriptional biomarkers for predicting development of TB: progress and clinical considerations. *Eur Respir J*. 2020

**Goletti D**, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: a multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. *Int J Infect Dis*. 2019 Dec 27. pii:S1201-9712(19)30504-1. doi: 10.1016/j.ijid.2019.12.031.PubMed PMID: 31887456.

Petrone L, Albrich WC, Tamarozzi F, Frischknecht M, Gomez-Morales MA, Teggi A, Hoffmann M, **Goletti D**. Species-specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis. *Parasite Immunol*. 2019 Dec 29:e12695. doi: 10.1111/pim.12695. [Epub ahead of print] PubMed PMID: 31884696.

Zabotti A, **Goletti D**, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. *Expert Opin Drug Saf*. 2020 Jan;19(1):69-82. doi: 10.1080/14740338.2020.1703946. Epub 2019 Dec 19. PubMed PMID: 31847608.

Larsen ES, Joensen UN, Poulsen AM, **Goletti D**, Johansen IS. Bacillus Calmette-Guérin immunotherapy for bladder cancer: A review of immunological aspects, clinical effects and BCG infections. *APMIS*. 2019 Nov 22. doi: 10.1111/apm.13011. [Epub ahead of print] Review. PubMed PMID: 31755155.

Musso M, Mosti S, Gualano G, Mencarini P, Urso R, Ghirga P, Rianda A, Del Nonno F, **Goletti D**, Palmieri F. Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis. *BMC Infect Dis*. 2019 Oct 22;19(1):882. doi: 10.1186/s12879-019-4494-1. PubMed PMID: 31640579; PubMed Central PMCID: PMC6806539.

Sotgiu G, **Goletti D**, Matteelli A. Global tuberculosis prevention: should we start from the beginning? *Eur Respir J*. 2019 Sep 12;54(3).

Sotgiu G, Saderi L, Petruccioli E, Aliberti S, Piana A, Petrone L, **Goletti D**. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. *J Infect*. 2019 Aug 29. pii: S0163-4453(19)30258-0.

Alonzi T, Petruccioli E, Vanini V, Fimia GM, **Goletti D**. Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry. *Eur J Histochem*. 2019 Jun 26;63(2). doi: 10.4081/ejh.2019.3044. PubMed PMID: 31243942

Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccocanti F, Sali M, Bondet V, Duffy D, Fimia GM, **Goletti D**, Delogu G. IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. *Int J Med Microbiol*. 2019 May 22. pii: S1438-4221(19)30097-9. doi:10.1016/j.ijmm.2019.05.005. [Epub ahead of print] PubMed PMID: 31147175

Cantini F, Niccoli L, Capone A, Petrone L, **Goletti D**. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. *Expert Opin Drug Saf*. 2019 May 8:1-11.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, **Goletti D**. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. *J Infect*. 2019 Apr 11.

Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, Murachelli S, Cannas A, Di Caro A, Navarra A, **Goletti D**, Girardi E, Palmieri F. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. *PLoS One*. 2019 Feb 28;14(2):e0212948.

Santos VS, **Goletti D**, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M,

Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. *Clin Microbiol Infect.* 2019 Feb;25(2):169-177.

Coluzzi F, Meniconi RL, Caruso D, Rivosecchi F, Petrone L, **Goletti D**, Ettore GM. Severe chest allodynia as an unusual first presentation of hydatid disease: a case report. *BMC Infect Dis.* 2019 Jan 9;19(1):37. doi: 10.1186/s12879-019-3670-7.

De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, **Goletti D**, Sanguinetti M, Manganelli R, De Spirito M, Delogu G. PE\_PGRS3 of *Mycobacterium tuberculosis* is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in *Mycobacterium smegmatis*. *Cell Microbiol.* 2018 Dec;20(12):e12952. doi: 10.1111/cmi.12952. Epub 2018 Sep 26. PubMed PMID: 30192424.

**Goletti D**, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denking CM, Cobelens F. Can we predict tuberculosis cure? What tools are available? *Eur Respir J.* 2018 Nov 8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review. PubMed PMID: 30361242.

De Maio F, Squeglia F, **Goletti D**, Delogu G. The Mycobacterial HBHA Protein: a Promising Biomarker for Tuberculosis. *Curr Med Chem.* 2018 Oct 29. doi: 10.2174/0929867325666181029165805. [Epub ahead of print] PubMed PMID: 30378481.

Sali M, Buonsenso D, D'Alfonso P, De Maio F, Ceccarelli M, Battah B, Palucci I, Chiacchio T, **Goletti D**, Sanguinetti M, Valentini P, Delogu G. Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. *J Infect.* 2018 Sep 26. pii: S0163-4453(18)30284-6.

De Maio F, Battah B, Palmieri V, Petrone L, Corrente F, Salustri A, Palucci I, Bellesi S, Papi M, Rubino S, Sali M, **Goletti D**, Sanguinetti M, Manganelli R, De Spirito M, Delogu G. PE\_PGRS3 of *Mycobacterium tuberculosis* is specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed in *Mycobacterium smegmatis*. *Cell Microbiol.* 2018 Sep 7:e12952.

Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, Delogu G, Ciccocanti F, Fimia GM, Blauenfeldt T, Ruhwald M, Duffy D, **Goletti D**. First description of agonist and antagonist IP-10 in urine of patients with active TB. *Int J Infect Dis.* 2018 Sep 7. pii: S1201-9712(18)34513-2.

Kik SV, Schumacher S, Maria Cirillo D, Churchyard G, Boehme C, **Goletti D**, Rangaka MX, Denking CM, Lienhardt C, Gilpin C, Matteelli A, Cobelens F. An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. *Eur Respir J.* 2018

Santos VS, **Goletti D**, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Cruu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. *Clin Microbiol Infect.* 2018 Aug 2. pii: S1198-743X(18)30535-4.

Blauenfeldt T, Petrone L, Del Nonno F, Baiocchini A, Falasca L, Chiacchio T, Bondet V, Vanini V, Palmieri F, Galluccio G, Casrouge A, Eugen-Olsen J, Albert ML, **Goletti D**, Duffy D, Ruhwald M. Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. *Front Immunol.* 2018 Jul 5;9:1456. doi: 10.3389/fimmu.2018.01456. eCollection 2018. PubMed PMID: 30026741; PubMed Central PMCID: PMC6041415.

Petrone L, Vanini V, Chiacchio T, Petruccioli E, Cuzzi G, Schininà V, Palmieri F, Ippolito G, **Goletti D**. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. *Tuberculosis (Edinb).* 2018 Jul;111:147-153. doi: 10.1016/j.tube.2018.06.005. Epub 2018 Jun 12. PubMed PMID: 30029901.A

Andrade JM, Custódio L, Romagnoli A, Reis CP, Rodrigues MJ, Garcia C, Petruccioli E, **Goletti D**, Faustino C, Fimia GM, Rijo P. Antitubercular and anti-inflammatory properties screening of natural products from *Plectranthus* species. *Future Med Chem.* 2018 Jun 29.

Schininà V, Albarello F, Cristofaro M, Di Stefano F, Fusco N, Cuzzi G, Arend SM, **Goletti D**, Busi Rizzi E. Diagnostic imaging of hepatic tuberculosis: case series. *Int J Tuberc Lung Dis.* 2018 Jul 1;22(7):779-787.

Orlando V, La Manna MP, **Goletti D**, Palmieri F, Lo Presti E, Joosten SA, La Mendola C, Buccheri S, Ottenhoff THM, Dieli F, Caccamo N. Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During *Mycobacterium Tuberculosis*



Infection and Correlate With Active Disease. *Front Immunol.* 2018 May 23;9:1119.

**Goletti D**, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. *Expert Rev Anti Infect Ther.* 2018 Jun 12:1-12.

Romagnoli A, Petruccioli E, Palucci I, Camassa S, Carata E, Petrone L, Mariano S, Sali M, Dini L, Girardi E, Delogu G, **Goletti D**, Fimia GM. Clinical isolates of the modern Mycobacterium tuberculosis lineage 4 evade host defense in human macrophages through eluding IL-1 $\beta$ -induced autophagy. *Cell Death Dis.* 2018 May 24;9(6):624.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Manna MP, Orlando V, Pinnetti C, Sampaolesi A, Antinori A, Caccamo N, **Goletti D**. Impact of antiretroviral and tuberculosis therapies on CD4(+) and CD8(+) HIV/M. tuberculosis-specific T-cell in co-infected subjects. *Immunol Lett.* 2018 Apr 7.

**Goletti D**, Montesano C, Mattei M, Migliori GB. Professor Massimo Amicosante, 1968-2017. *Int J Tuberc Lung Dis.* 2018 Feb 1;22(2):236. doi: 10.5588/ijtld.17.0772. PubMed PMID: 29506622.

Carvalho I, **Goletti D**, Manga S, Silva DR, Manissero D, Migliori G. Managing latent tuberculosis infection and tuberculosis in children. *Pulmonology.* 2018 Mar - Apr;24(2):106-114. doi: 10.1016/j.rppnen.2017.10.007. Epub 2018 Mar 2. PubMed PMID: 29502937.

Baddley JW, Cantini F, **Goletti D**, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor- $\alpha$  agents). *Clin Microbiol Infect.* 2018 Feb 6. pii: S1198-743X(18)30030-2. doi: 10.1016/j.cmi.2017.12.025.

**Goletti D**, Lee MR, Wang JY, Walter N, Ottenhoff THM. Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. *Respirology.* 2018 Feb 18. doi: 10.1111/resp.13272.

Paolino M, Brindisi M, Vallone A, Butini S, Campiani G, Nannicini C, Giuliani G, Anzini M, Lamponi S, Giorgi G, Sbardella D, Ferraris DM, Marini S, Coletta M, Palucci I, Minerva M, Delogu G, Pepponi I, **Goletti D**, Cappelli A, Gemma S, Brogi S. Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. *ChemMedChem.* 2018 Mar 6;13(5):422-430. doi: 10.1002/cmdc.201700759. Epub 2018 Feb 14. PubMed PMID: 29334428.

Parlato S, Chiacchio T, Salerno D, Petrone L, Castiello L, Romagnoli G, Canini I, **Goletti D**, Gabriele L. Impaired IFN- $\alpha$ -mediated signal in dendritic cells differentiates active from latent tuberculosis. *PLoS One.* 2018 Jan 10;13(1):e0189477. doi: 10.1371/journal.pone.0189477. eCollection 2018.

Palucci I, Matic I, Falasca L, Minerva M, Maulucci G, De Spirito M, Petruccioli E, **Goletti D**, Rossin F, Piacentini M, Delogu G. Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. *J Intern Med.* 2017 Dec 4. doi: 10.1111/joim.12714.

Linda Petrone, Valentina Vanini, Massimo Amicosante, Angela Corpolongo, Maria Angeles Gomez Morales, Alessandra Ludovisi, Giuseppe Ippolito, Edoardo Pozio, Antonella Teggi, **Delia Goletti. Parasite Immunology, in press**

Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; **TBvac2020 Consortium. TBvac2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Front Immunol. 2017 Oct 4;8:1203.**

Chiacchio T, Delogu G, Vanini V, Cuzzi G, De Maio F, Pinnetti C, Sampaolesi A, Antinori A, **Goletti D**. Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. *PLoS One.* 2017 Aug 24;12(8):e0183846.

Jones A, Pitts M, Al Dulayymi JR, Gibbons J, Ramsay A, **Goletti D**, Gwenin CD, Baird MS. New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. *PLoS One.* 2017 Aug 14;12(8):e0181414.

Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F, Ippolito G, **Goletti D**. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. *Tuberculosis (Edinb).* 2017 Sep;106:38-43.

Scriba TJ, Carpenter C, Carrasco Pro S, Sidney J, Musvosvi M, Rozot V, Seumois G, Rosales SL, Vijayanand P, **Goletti D**, Makgotlho E, Hanekom W, Hatherill M, Peters B, Sette A, Lindestam Arlehamn CS. Differential Recognition of Mtb-specific Epitopes as a Function of Tuberculosis Disease History. **Am J Respir Crit Care Med.** 2017 Jul 31. doi: [10.1164/rccm.201706-12080C](https://doi.org/10.1164/rccm.201706-12080C).

Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, **Goletti D**. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. **Mediators Inflamm.** 2017;2017:8909834.

Bénet T, Sánchez Picot V, Messaoudi M, Chou M, Eap T, Wang J, Shen K, Pape JW, Rouzier V, Awasthi S, Pandey N, Bavdekar A, Sanghavi S, Robinson A, Rakoto-Andrianarivelo M, Sylla M, Diallo S, Nymadawa P, Naranbat N, Russomando G, Basualdo W, Komurian-Pradel F, Endtz H, Vanhems P, Paranhos-Baccalà G; Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network . Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. **Clin Infect Dis.** 2017

Solovic I, Abubakar I, Sotgiu G, Dara M, **Goletti D**, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratziau C, Migliori GB. Standard operating procedures for tuberculosis care. **Eur Respir J.** 2017 Jun 1;49(6). pii: [1700515](https://pubmed.ncbi.nlm.nih.gov/1700515/).

Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Codecasa LR, Ottenhoff TH, Denkinger CM, **Goletti D**. Long-lasting tuberculous pleurisy. **Eur Respir J.** 2017 May 25;49(5). pii: [1700356](https://pubmed.ncbi.nlm.nih.gov/1700356/).

Camassa S, Palucci I, Iantomasi R, Cubeddu T, Minerva M, De Maio F, Jouny S, Petruccioli E, **Goletti D**, Ria F, Sali M, Sanguinetti M, Manganelli R, Rocca S, Brodin P, Delogu G. Impact of pe\_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. **Front Cell Infect Microbiol.** 2017 Apr 21;7:137. doi: [10.3389/fcimb.2017.00137](https://doi.org/10.3389/fcimb.2017.00137). eCollection 2017.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, **Goletti D**. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. **Semin Arthritis Rheum.** 2017 Mar 22.

La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, **Goletti D**, Caccamo N. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. **PLoS One.** 2017 Feb 16;12(2):e0171358.

Girardi E, Sañé Schepisi M, **Goletti D**, Bates M, Mwaba P, Yeboah-Manu D, Ntoumi F, Palmieri F, Maeurer M, Zumla A, Ippolito G. The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. **Int J Infect Dis.** 2017 Mar;56:45-53.

Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Palmieri F, Cirillo DM, Ippolito G, **Goletti D**. Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. **Int J Mycobacteriol.** 2016 Dec;5 Suppl 1:S25-S26.

Petruccioli E, Vanini V, Chiacchio T, Cirillo DM, Palmieri F, Ippolito G, **Goletti D**. Modulation of interferon-gamma response to QuantiFERON-TB-plus detected by enzyme-linked immunosorbent assay in patients with active and latent tuberculosis infection. **Int J Mycobacteriol.** 2016 Dec;5 Suppl 1:S143-S144.

Chiacchio T, Petruccioli E, Pepponi I, Vanini V, Gualano G, Cirillo D, Palmieri F, Ippolito G, **Goletti D**. Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment. **Int J Mycobacteriol.** 2016 Dec;5 Suppl 1:S141-S142.

Matucci A, Cammelli D, Cantini F, **Goletti D**, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. **Expert Opin Drug Saf.** 2016 Dec;15(sup1):3-10. PubMed PMID: [27924646](https://pubmed.ncbi.nlm.nih.gov/27924646/).

Tocci G, **Goletti D**, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. **Expert Opin Drug Saf.** 2016 Dec;15(sup1):55-61. PubMed PMID: [27924645](https://pubmed.ncbi.nlm.nih.gov/27924645/).

Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V,

**Goletti D**, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. **Expert Opin Drug Saf.** 2016 Dec;15(sup1):35-54. PubMed PMID: 27924644.

Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, **Goletti D**, Cantini F. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. **Expert Opin Drug Saf.** 2016 Dec;15(sup1):11-34. PubMed PMID: 27924643.

Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, **Goletti D**. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. *Eur Respir J.* 2016 Nov 11. pii: **ERJ-01012-2016**. doi: **10.1183/13993003.01012-2016**.

Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, **Goletti D**, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. **Eur Respir J.** 2016 Nov;48(5):1411-1419.

Petrone L, Cannas A, Vanini V, Cuzzi G, Aloï F, Nsubuga M, Sserunkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Antinori A, Pucci L, Reither K, **Goletti D**. Blood and urine inducible protein 10 as potential markers of disease activity. **Int J Tuberc Lung Dis.** 2016 Nov;20(11):1554-1561.

Polverino E, Bothamley GH, **Goletti D**, Heyckendorf J, Sotgiu G, Aliberti S. The best of respiratory infections from the 2015 European Respiratory Society International Congress. **ERJ Open Res.** 2016 Jul 11;2(3).

Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Cirillo DM, Palmieri F, Ippolito G, **Goletti D**. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. **J Infect.** 2016 Oct 4.

Delogu G, Vanini V, Cuzzi G, Chiacchio T, De Maio F, Battah B, Pinnetti C, Sampaolesi A, Antinori A, Goletti D. Lack of response to HBHA in HIV-infected patients with latent tuberculosis infection. **Scand J Immunol.** 2016 Sep 16.

Cirillo DM, Barcellini L, **Goletti D**. Preliminary data on precision of QuantiFERON-TB Plus performance. **Eur Respir J.** 2016 Sep;48(3):955-6.

Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, Tran R, **Goletti D**, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Teixeira V, Ward B, Gratziau C, Migliori GB. Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. **Eur Respir J.** 2016

Petruccioli E, Navarra A, Petrone L, Vanini V, Cuzzi G, Gualano G, Palmieri F, Girardi E, **Goletti D**. Use of several immunological markers to model the probability of active tuberculosis. **Diagn Microbiol Infect Dis.** 2016 Jun 14.

**Goletti D**, Petruccioli E, Joosten SA, Ottenhoff TH. Tuberculosis Biomarkers: From Diagnosis to Protection. **Infect Dis Rep.** 2016 Jun 24;8(2):6568.

Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di Serio C, Ferrarese M, **Goletti D**, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. **Eur Respir J.** 2016 Jul 7.

Dara M, Solovic I, **Goletti D**, Sotgiu G, Centis R, D'Ambrosio L, Ward B, Teixeira V, Gratziau C, Migliori GB. Preventing and controlling tuberculosis among refugees in Europe: more is needed. **Eur Respir J.** 2016 Jul;48(1):272-4.

Joosten SA, van Meijgaarden KE, Del Nonno F, Baiocchi A, Petrone L, Vanini V, Smits HH, Palmieri F, **Goletti D**, Ottenhoff TH. Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. **PLoS Pathog.** 2016 Jun 15;12(6):e1005687.

Vennarecci G, Manfredelli S, Guglielmo N, Laurenzi A, **Goletti D**, Ettore GM. Major liver resection for recurrent hydatid cyst of the liver after suboptimal treatment. **Updates Surg.** 2016 Apr 28.

Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, **Goletti D**, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Ward B, Teixeira V, Gratziau C, Migliori GB. Call for urgent actions to ensure access to early

diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease. **Eur Respir J.** 2016 May;47(5):1345-7.

Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, Dal Monte P, Di Serio C, **Goletti D**, Lombardi G, Lipman M, Rancoita PM, Tadolini M, Cirillo DM. First independent evaluation of QuantiFERON-TB Plus performance. **Eur Respir J.** 2016 Feb 11.

Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). **Autophagy.** 2016 Jan 2;12(1):1-222. PubMed PMID: 26799652.

Boer MC, van Meijgaarden KE, **Goletti D**, Vanini V, Prins C, Ottenhoff TH, Joosten SA. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. **Tuberculosis (Edinb).** 2016 Mar;97:163-71.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, **Goletti D**; Italian board for the Tailored BIOlogic therapy (ITABIO). Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. **Semin Arthritis Rheum.** 2015 Oct 22. pii: S0049-0172(15)00241-3.

Petrone L, Vanini V, Petruccioli E, Ettore GM, Schininà V, Busi Rizzi E, Ludovisi A, Corpolongo A, Ippolito G, Pozio E, Teggi A, **Goletti D**. Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts. **PLoS Negl Trop Dis.** 2015 Nov 17;9(11):e0004209.

Sali M, Buonsenso D, **Goletti D**, D'Alfonso P, Zumbo A, Fadda G, Sanguinetti M, Delogu G, Valentini P. Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children. **PLoS One.** 2015 Oct 6;10(10):e0138952.

Petrone L, Cannas A, Aloï F, Nsubuga M, Sserumkuma J, Nazziwa RA, Jugheli L, Lukindo T, Girardi E, Reither K, **Goletti D**. Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children. **Biomed Res Int.** 2015;2015:589471.

Carpenter C, Sidney J, Kolla R, Nayak K, Tomiyama H, Tomiyama C, Padilla OA, Rozot V, Ahamed SF, Ponte C, Rolla V, Antas PR, Chandele A, Kenneth J, Laxmi S, Makgotlho E, Vanini V, Ippolito G, Kazanova AS, Panteleev AV, Hanekom W, Mayanja-Kizza H, Lewinsohn D, Saito M, McElrath MJ, Boom WH, **Goletti D**, Gilman R, Lyadova IV, Scriba TJ, Kallas EG, Murali-Krishna K, Sette A, Lindestam Arlehamn CS. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. **Tuberculosis (Edinb).** 2015 Aug 1.

Petruccioli E, Petrone L, Vanini V, Cuzzi G, Navarra A, Gualano G, Palmieri F, Girardi E, **Goletti D**. Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. **J Infect.** 2015 Aug 5.

Spinicci M, Mencarini J, **Goletti D**, Mantella A, Della Malva N, Bartoloni A, Bartalesi F. Discordance between the QuantiFERON-TB Gold In-Tube and Tuberculin Skin Test: need for a further step? **Eur Respir J.** 2015 Jul 23. pii: ERJ-00403-2015. doi: 10.1183/13993003.00403-2015.

Guggino G, Orlando V, Cutrera S, La Manna MP, Di Liberto D, Vanini V, Petruccioli E, Dieli F, **Goletti D**, Caccamo N. Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease. **Immunol Lett.** 2015 Aug;166(2):87-91. doi: 10.1016/j.imlet.2015.05.019.

El Daker S, Sacchi A, Tempestilli M, Carducci C, **Goletti D**, Vanini V, Colizzi V, Lauria FN, Martini F, Martino A. Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. **PLoS One.** 2015 Apr 16;10(4):e0123772

Xia H, Wang X, Li F, Longuet C, Vernet G, **Goletti D**, Zhao Y, Lagrange PH. Diagnostic Values of the QuantiFERON-TB Gold In-Tube Assay Carried out in China for Diagnosing Pulmonary Tuberculosis. **PLoS One.** 2015 Apr 13;10(4):e0121021.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, **Goletti D**, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Gogvadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pomba MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-

Palmer A, Sotgiu G, Sulis G, A Torres-Duque C, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Towards tuberculosis elimination: an action framework for low-incidence countries. **Eur Respir J.** 2015 Mar 18.

Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunski R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Dominguez J, Duarte R, Fløe A, Fresard I, García-García JM, **Goletti D**, Halm P, Hellwig D, Henninger E, Heykes-Uden H, Horn L, Kruczak K, Latorre I, Pache G, Rath H, Ringshausen FC, Seminario Ruiz A, Solovic I, de Souza-Galvão ML, Widmer U, Witte P, Lange C; TBNET. Risk Assessment of Tuberculosis in Contacts by Interferon- $\gamma$  Release Assays (IGRAs). A TBNET Study. **Am J Respir Crit Care Med.** 2015 Mar 12.

Sañé Schepisi M, Parracino MP, Mammone A, Bellagamba R, Pinnetti C, Cicalini S, Sampaolesi A, Ammassari A, **Goletti D**, Girardi E. Immune Status and Serial Quantiferon-TB Gold In-Tube Screening for Latent Mycobacterium tuberculosis Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. **J Infect Dis.** 2015 Jan 26.

Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, **Goletti D**; on behalf of SAFE BIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. **Autoimmun Rev.** 2015 Jan 21. pii: S1568-9972(15)00026-9.

Petrone L, Vanini V, Petruccioli E, Ettore GM, Busi Rizzi E, Schininà V, Girardi E, Ludovisi A, Gómez-Morales MA, Pozio E, Teggi A, **Goletti D**. IL-4 specific-response in whole blood associates with human Cystic Echinococcosis and cyst activity. **J Infect.** 2014 Oct 22.

Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Ohmiti K, **Goletti D**, Bart PA, Hanekom W, Scriba TJ, Nicod L, Pantaleo G, Harari A. Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. **Clin Infect Dis.** 2014 Oct 31. pii: ciu795.

De Visser V, Sotgiu G, Lange C, Aabye MG, Bakker M, Bartalesi F, Brat K, Chee CB, Dheda K, Dominguez J, Eyuboglu F, Ghanem M, **Goletti D**, Dilektasli AG, Guglielmetti L, Koh WJ, Latorre I, Losi M, Polanova M, Ravn P, Ringshausen FC, Rumetshofer R, de Souza-Galvão ML, Thijssen S, Bothamley G, Bossink A; for the TBNET. False-negative interferon- $\gamma$  release assay results in active tuberculosis: a TBNET study. **Eur Respir J.** 2014 Oct 30.

Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, **Goletti D**, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccia PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C; TBNET. Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. **Am J Respir Crit Care Med.** 2014 Nov 15;190(10):1168-76.

Cantini F, Boccia S, **Goletti D**, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF- $\alpha$ ) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. **Int J Rheumatol.** 2014;2014:926836.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E, **Goletti D**. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. **J Infect.** 2014 Dec;69(6):533-45.

Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D**. A toolbox for tuberculosis (TB) diagnosis: an Indian multi-centric study (2006-2008); evaluation of serological assays based on PGL-Tb1 and ESAT-6/CFP10 antigens for TB diagnosis. **PLoS One.** 2014 May 5;9(5):e96367.

Cantini F, Boccia S, **Goletti D**, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF- $\alpha$ ) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. **Int J Rheumatol.** 2014

Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D**. A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multi-Centric Study (2006-2008); Evaluation of Serological Assays Based on PGL-Tb1 and ESAT-6/CFP10 Antigens for TB Diagnosis. **PLoS One.** 2014 May 5;9(5):e96367.



Cantini F, Prignano F, **Goletti D**. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. **J Rheumatol Suppl. 2014 May;91:78-82.**

Cantini F, Niccoli L, **Goletti D**. Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) Targeted Biologics and Recently Licensed TNF- $\alpha$  Inhibitors: Data from Clinical Trials and National Registries. **J Rheumatol Suppl. 2014 May;91:56-64.**

Cantini F, Niccoli L, **Goletti D**. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. **J Rheumatol Suppl. 2014 May;91:47-55.**

**Goletti D**, Sanduzzi A, Delogu G. Performance of the Tuberculin Skin Test and Interferon- $\gamma$  Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches. **J Rheumatol Suppl. 2014 May;91:24-31.**

Delogu G, **Goletti D**. The spectrum of tuberculosis infection: new perspectives in the era of biologics. **J Rheumatol Suppl. 2014 May;91:11-6.**

Cantini F, **Goletti D**. Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. **J Rheumatol Suppl. 2014 May;91:1-3.**

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, **Goletti D**, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsç-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; for the TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. **Eur Respir J. 2014 Mar 23.**

Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di Giacomo C, Pucci L, Montalbano M, Lionetti R, Testa A, Lapa D, Navarra A, Visco-Comandini U, **Goletti D**. High urine IP-10 levels associate with chronic HCV infection. **J Infect. 2014 Feb 26.** pii: S0163-4453(14)00044-9. doi: 10.1016/j.jinf.2014.02.008.

Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G, Bosu R, Ambrosi A, Codecasa LR, **Goletti D**, Matteelli A, Ntinginya EN, Aloï F, Heinrich N, Reither K, Cirillo DM. miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. **PLoS One. 2013 Nov 21;8(11):e80149.**

Petrone L, Cuzzi G, Colace L, Ettorre GM, Busi-Rizzi E, Schininà V, Pucillo L, Angeletti C, Pane S, Di Caro A, Bordi E, Girardi E, Pozio E, Corpolongo A, Teggi A, Brunetti E, **Goletti D**. Cystic echinococcosis in a single tertiary care center in rome, Italy. **Biomed Res Int. 2013;2013:978146.**

Dorhoi A, Iannaccone M, Farinacci M, Faé KC, Schreiber J, Moura-Alves P, Nouailles G, Mollenkopf HJ, Oberbeck-Müller D, Jörg S, Heinemann E, Hahnke K, Löwe D, Del Nonno F, **Goletti D**, Capparelli R, Kaufmann SH. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. **J Clin Invest. 2013 Oct 1.**

Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D**. A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multicentric Study (2006-2008). Evaluation of QuantiFERON-TB Gold in Tube for TB Diagnosis. **PLoS One. 2013 Sep 6;8(9):e73579.**

Petrucchioli E, Petrone L, Vanini V, Sampaolesi A, Gualano G, Girardi E, Palmieri F, **Goletti D**. IFN $\gamma$ /TNF $\alpha$  specific-cells and effector memory phenotype associate with active tuberculosis. **J Infect. 2013 Feb 24.** doi:pii: S0163-4453(13)00028-5. 10.1016/j.jinf.2013.02.004.

Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-Blanchet C, Petruccioli E, Hanekom W, **Goletti D**, Bart PA, Nicod L, Pantaleo G, Harari A. Mycobacterium tuberculosis-specific CD8(+) T cells are functionally and phenotypically different between latent infection and active disease. **Eur J Immunol. 2013 Mar 4.** doi: 10.1002/eji.201243262.

**Goletti D**, Petruccioli E, Romagnoli A, Piacentini M, Fimia GM. Autophagy in Mycobacterium tuberculosis infection: A passepartout to flush the intruder out? **Cytokine Growth Factor Rev. 2013 Feb 7.** doi:pii: S1359-6101(13)00003-

**8. 10.1016/j.cytogfr.2013.01.002. [Epub ahead of print] PubMed PMID: 23395260.**

Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group. Health care indexscore and risk of death following tuberculosis diagnosis in HIV-positivepatients. **Int J Tuberc Lung Dis.** 2013 Feb;17(2):198-206. doi: 10.5588/ijtld.12.0224. PubMed PMID: 23317955.

Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo DM, Wagner D, Kampmann B, Goletti D, Juers T and Sester M. TBNET – COLLABORATIVE RESEARCH ON TUBERCULOSIS IN EUROPE. **European Journal of Microbiology and Immunology** 2012. 4, pp. 264–274. DOI: 10.1556/EuJMI.2.2012.4.4

Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, Fiori G, Li Gobbi F, Mantella A, Benucci M, Prignano F, Pimpinelli N, Matucci Cerinic M, Girardi E, Bartoloni A. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. **J Infect.** 2012 Oct 24. doi:pii: S0163-4453(12)00303-9. 10.1016/j.jinf.2012.10.017.

Lagrange PH, Thangaraj SK, Dayal R, Despande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Lepotier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, **Goletti D.** A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006–2008): microbiological results. **PLoS One.** 2012;7(8):e43739. Epub 2012 Aug 24.

Romagnoli A, Etna MP, Giacomini E, Pardini M, Remoli ME, Corazzari M, Falasca L, **Goletti D,** Gafa V, Simeone R, Delogu G, Piacentini M, Brosch R, Fimia GM, Coccia EM. ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells. **Autophagy.** 2012 Sep 1;8(9):1357-70.

Greco E, Quintiliani G, Santucci MB, Serafino A, Ciccaglione AR, Marcantonio C, Papi M, Maulucci G, Delogu G, Martino A, **Goletti D,** Sarmati L, Andreoni M, Altieri A, Alma M, Caccamo N, Di Liberto D, De Spirito M, Savage ND, Nisini R, Dieli F, Ottenhoff TH, Fraziano M. Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. **Proc Natl Acad Sci U S A.** 2012 May 22;109(21):E1360-8.

Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, **Goletti D,** Ison MG, Jones CE, Kampmann B, Kotton CN, Lange C, Ljungman P, Milburn H, Morris MI, Muller E, Muñoz P, Nellore A, Rieder HL, Sester U, Theodoropoulos N, Wagner D, Sester M. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. **Eur Respir J.** 2012 Apr 10.

**Goletti D,** Sester M. Screening for latent infection with Mycobacterium tuberculosis: a plea for targeted testing in low endemic regions. **Expert Rev Mol Diagn.** 2012 Apr;12(3):231-4.

Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, Alba L, Giancola ML, Conte A, Schininà V, Busi Rizzi E, Girardi E, **Goletti D.** IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. **J Infect.** 2012 Jul;65(1):49-59.

Petruccioli E, Romagnoli A, Corazzari M, Coccia EM, Butera O, Delogu G, Piacentini M, Girardi E, Fimia GM, **Goletti D.** Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages. **J Infect Dis.** 2012 May;205(9):1425-35.

Laurenti P, Bruno S, Quaranta G, La Torre G, Cairo AG, Nardella P, Delogu G, Fadda G, Pirronti T, Geraci S, Pelargonio S, Lauria FN, **Goletti D,** Ricciardi G. Tuberculosis in sheltered homeless population of rome: an integrated model of recruitment for risk management. **Scientific World Journal.** 2012;2012:396302.

Cingolani A, Cozzi Lepri A, Castagna A, **Goletti D,** De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naïve HIV-infected patients presenting with tuberculosis as AIDS-defining condition. **Clin Infect Dis.** 2012 Mar;54(6):853-61.

Chiacchio T, Petruccioli E, Vanini V, Butera O, Cuzzi G, Petrone L, Matteucci G, Lauria FN, Franken KL, Girardi E, Ottenhoff TH, **Goletti D.** Higher Frequency of T-Cell Response to *M. tuberculosis* Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. **PLoS One.** 2011;6(11):e27539.

Diel R, **Goletti D,** Lange C, Manissero D. Interferon- $\gamma$  release assays for the diagnosis of latent Mycobacterium tuberculosis infection. **Eur Respir J.** 2011 Nov;38(5):1238-9.

Borgia P, Cambieri A, Chini F, Coltella L, Delogu G, Di Rosa E, Fadda G, Giorgi Rossi P, Girardi E, **Goletti D**, Guasticchi G, Morrone A, Pezzotti P, Romagnoli C, Sacerdote M, Russo C, Villani A, Zarelli L. Suspected transmission of tuberculosis in a maternity ward from a smear-positive nurse: preliminary results of clinical evaluations and testing of neonates potentially exposed, Rome, Italy, 1 January to 28 July 2011. **Euro Surveill. 2011 Oct 6;16(40).**

Busi Rizzi E, Schinina' V, Cristofaro M, **Goletti D**, Palmieri F, Bevilacqua N, Lauria FN, Girardi E, Bibbolino C. Detection of Pulmonary tuberculosis: comparing MR imaging with HRCT. **BMC Infect Dis. 2011 Sep 16;11:243.**

Syed Ahamed Kabeer B, Raja A, Raman B, Thangaraj S, Leportier M, Ippolito G, Girardi E, Lagrange PH, **Goletti D**. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. **BMC Infect Dis. 2011 May 19;11(1):135.**

Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua , Molicotti P , Zanetti S, Lauria FN, Grisetti S, Magnavita N, Fadda G, Girardi E, **Goletti D**. Methylated HBHA Produced in *M. smegmatis* Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. **PLoS ONE 6(3): e18315, 2011.**

Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, Pasticci MB, Mazzolla R, Goletti D, Butera O, Bruchfeld J, Gaines H, Gerogianni I, Tuuminen T, Ferrara G, Eugen-Olsen J, Ravn P; on behalf of TBNET. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with *M. tuberculosis*. **Tuberculosis: 2011 May;91(3):260-267.**

Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria FN, Pucci L, Girardi E, **Goletti D**. IP-10 detection in urine is associated with lung diseases. **BMC Infect Dis. 2010 Nov 22;10:333**

Diel R, **Goletti D**, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D. Interferon- $\gamma$  release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. **Eur Respir J. 2011 Jan;37(1):88-99.**

Girardi E, **Goletti D**. Do IFN- $\gamma$ -release assays predict the risk of TB? New evidence from a study on patients with silicosis. **Expert Rev Anti Infect Ther 2010 Oct;8(10):1105-8.**

**Goletti D**, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH. Is IP-10 an accurate marker for detecting *M. tuberculosis*-specific response in HIV-infected persons? **PLoS One. 2010 Sep 7;5(9):e12577.**

Lange C, Bossink A, Eberhardt R, **Goletti D**, Jafari C, Latorre I, Kirsten D, Losi M, Migliori GB, Sotgiu G. Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. **Thorax. 2010 Sep;65(9):842; author reply 842-3.**

Sotgiu G, Centis R, D'ambrosio L, De Lorenzo S, D'arcy Richardson M, Lange C, Manissero D, Migliori GB; TBNET MDR-TB project. Development of a standardized tool to survey MDR-/XDR-TB case management in Europe. **Eur Respir J. 2010 Jul;36(1):208-11. Multicenter study.**

Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, **Goletti D**, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. **Eur Respir J. 2010 Nov;36(5):1185-206.**

**Goletti D**, Raja A, Ahamed Kabeer BS, Rodrigues C, Sodha A, Butera O, Carrara S, Vernet G, Longuet C, Ippolito G, Thangaraj S, Leportier M, Girardi E, Lagrange PH. IFN $\gamma$ , but not IP10, MCP2 or IL2 response to RD1 selected peptides associates to active tuberculosis. **J Infect. 2010 May 11.**

Butera O, Chiacchio T, Carrara S, Casetti R, Vanini V, Meraviglia S, Guggino G, Dieli F, Vecchi M, Lauria FN, Marruchella A, Laurenti P, Singh M, Caccamo N, Girardi E, **Goletti D**. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. **BMC Infect Dis. 2009 Nov 21;9:182.**

**Goletti D**, Butera O, Vanini V, Lauria FN, Lange C, Franken KL, Angeletti C, Ottenhoff TH, Girardi E. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. **Eur Respir J. 2009 Nov 19.**

Podlekareva DN, Mcroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E,

Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. **AIDS. 2009 Nov 27;23(18):2485-95. Multicenter study.**

Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, Vanini V, Girardi E, **Goletti D**, D'Amelio R, Nisini R. Detection of IL-2 in addition to IFN-gamma discriminates active tuberculosis patients, latently infected individuals and controls. **Clin Microbiol Infect. 2010 Aug;16(8):1282-4.**

Girardi E, Angeletti C, Puro V, Sorrentino R, Magnavita N, Vincenti D, Carrara S, Butera O, Ciufoli AM, Squarcione S, Ippolito G, **Goletti D**. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. **Euro Surveill. 2009 Oct 29;14(43).**

Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, **Goletti D**, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV-infection. **Eur Respir J. 2010 Mar;35(3):619-26.**

Jafari C, Thijsen S, Sotgiu G, **Goletti D**, Benítez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, Richeldi L, Ernst M, Lange C; Tuberculosis Network European Trialsgroup. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. **Am J Respir Crit Care Med. 2009 Oct 1;180(7):666-73.**

Sargentini V, Mariotti S, Carrara S, Gagliardi MC, Teloni R, **Goletti D**, Nisini R. Cytometric detection of antigen-specific IFN-gamma/IL-2 secreting cells in the diagnosis of tuberculosis. **BMC Infect Dis. 2009 Jun 23;9:99.**

Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, Borsellino G, **Goletti D**. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis. **Clin Exp Immunol. 2009 Jun;156(3):463-70.**

Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, **Goletti D**, Bossink A, Magdorf K, Hölscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM; C. Lange; TBNET. LTBI: latent tuberculosis infection or lasting immune responses to *M. tuberculosis*? A TBNET consensus statement. **Eur Respir J. 2009 May;33(5):956-73.**

Bartalesi F, Vicidomini S, **Goletti D**, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. **Eur Respir J. 2009 Mar;33(3):586-93. Epub 2008**

Casetti R, Martino A, Sacchi A, Agrati C, **Goletti D**, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? **Blood. 2008 Dec 1;112(12):4776-7; author reply 4777.**

**Goletti D** and GB Migliori. Respiratory Society. **Expert Reviews in Respiratory research, 2008 Dec 1;2(6):707-711.**

Casetti R, Martino A, Sacchi A, Agrati C, **Goletti D**, Martini F. Do human gammadelta T cells respond to M tuberculosis protein antigens? **Blood. 2008 Dec 1;112(12):4776-7.**

**Goletti D**, Stefania C, Butera O, Amicosante M, Ernst M, Sauzullo I, Vullo V, Cirillo D, Borroni E, Markova R, Drenska R, Dominguez J, Latorre I, Angeletti C, Navarra A, Petrosillo N, Lauria FN, Ippolito G, Migliori GB, Lange C, Girardi E. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. **PLoS ONE. 2008;3(10):e3417.**

Cannas A, **Goletti D**, Girardi E, Chiacchio T, Calvo L, Cuzzi G, Piacentini M, Melkonyan H, Umansky SR, Lauria FN, Ippolito G, Tomei LD. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. **Int J Tuberc Lung Dis. 2008; 12:146-51**

**Goletti D**, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, Toossi Z. Response to *M. tuberculosis* selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. **BMC Infectious Diseases 2008; 8:11**

**Goletti D**, Carrara S, Vincenti D, Girardi E. T cell responses to commercial *M. tuberculosis*-specific antigens in HIV-infected patients. **Clin Inf Dis 2007; 45: 1652-54.**

Palazzo R, Spensieri F, Massari M, Fedele G, Frasca L, Carrara S, **Goletti D**, Ausiello CM. In-house bulk and single cell antigen-specific whole blood Interferon-gamma assays for surveillance of *M. tuberculosis* infection. **Clin Vaccine Immunol**, 2007; 15:327-337.

Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, Girardi E, **Goletti D**. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. **Clin Exp Immunol**. 2007;150(1):91-8.

Girardi E, Loffredo M, Alessandrini A, Anzidei G, **Goletti D**. A two-step approach for screening contacts of active tuberculosis. **Infection**. 2007; 35(2):122-3.

**Goletti D**, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, Anzidei G, Nisii C, Ippolito G, Poccia F, Girardi E. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to *Mycobacterium tuberculosis*: a pilot study. **Respir Res** 2007;8:5.

Girardi E, **Goletti D**, Ippolito G. Should individuals who are tuberculin skin test negative and positive to RD1-IFN-gamma assay receive preventive therapy? **Am J Respir Crit Care Med**. 2007 Jan 15;175(2):198-199.

**Goletti D**, Macchia I, Leone P, Pace M, Sernicola L, Pavone-Cossut MR, Mayrella MT, Cafaro A, Ensoli B, Titti F. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. **Med Sci Monit**. 2006 Oct;12(10):BR330-40.

**Goletti D**, Butera O, Bizzoni F, et al. Selective effector or memory response of RD1-specific CD4+ T cells in patients with different stages of tuberculosis. **J Infect Dis**, 2006, 194:984-992

**Goletti D**, Carrara S, Vincenti D, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. **Clin Microbiol Infect**, 2006, 12:544-550.

**Goletti D**, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. **Clin Diagn Lab Immunol**. 2005, 12:1311-1316.

Palmieri F, Cicalini S, Froio N, Busi Rizzi E, Macrì G, Goletti D, Festa A, Petrosillo N. Pulmonary Cryptosporidiosis in an AIDS Patient: successful treatment with paromomycin plus azithromycin. **International Journal of STD&AIDS**, 2005, 189:624-633.

Palmieri F, Petrosillo N, Paglia MG, Conte A, **Goletti D**, Pucillo LP, Menegon M, Sannella A, Severini C, Majori G. Genetic confirmation of quinine-resistant plasmodium falciparum malaria in a traveller from Mozambique, followed by a post-malaria neurological syndrome **Journal of Clinical Microbiology**, 2004, 42:5424-6.

**Goletti D**, Carrara S, Vincenti D, Giacomini E, Fattorini L, Garbuglia AR, Capobianchi MR, Alonzi, Fimia GM, Federico M, Poli G and Coccia E. *Mycobacterium tuberculosis* inhibits Human Immunodeficiency Virus replication in monocyte-derived macrophages. **Journal Infectious Diseases**, 2004, 189:624-33.

Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, **Goletti D**. Use of a T-cell-based assay for monitoring efficacy of anti-tuberculosis therapy. **Clinical Infectious Diseases**, 2004, 38:754-6.

Gioia C, Agrati C, **Goletti D**, Vincenti D, Carrara S, Amicosante M, Casarini M, Giosue S, Puglisi G, Rossi A, Colizzi V, Pucillo LP, Poccia F. Different cytokine production and effector/memory dynamics of  $\alpha\beta+$  or  $\gamma\delta+$  T-cell subsets in the peripheral blood of patients with active pulmonary tuberculosis. **Int J Immunopathol Pharmacol**, 2003;16:247-252.

Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, Palmieri F, Armignacco O, Ippolito G, Girardi E, Amicosante M, **Goletti D**. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. **Mol Med**, 2003;9:105-11.

Antonucci G, **Goletti D**, Lanini S, Girardi E, Loiacono O. HIV/HCV co-infection: putting the pieces of the puzzle together. **Cell Death Differ**, 2003 Suppl 1:S25-6.

D'Offizi G, Ciapparoni V, Gioia C, **Goletti D**, Agrati C, Pucillo LP, Narciso P, Poccia F. The loss of CMV-specific CD27(-) T-cell effectors in a patient with recurrences of CMV retinitis is independent of HIV-1 viremia. **Infection**. 2002;30:323-5.



Martini F, Poccia F, **Goletti D**, Carrara S, Vincenti D, D'Offizi G, Agrati C, Ippolito G, Colizzi V, Pucillo LP, Montesano C. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. **J Infect Dis.** **2002;186:847-50.**

**Goletti D**, Kinter AL, Coccia EM, Battistini A, Petrosillo N, Ippolito G, Poli G. Interleukin (IL)-4 inhibits phorbol-ester induced HIV-1 expression in chronically infected U1 cells independently from the autocrine effect of endogenous tumour necrosis factor-alpha, IL-1beta, and IL-1 receptor antagonist. **Cytokine.** **2002;17:28-35.**

Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, **Goletti D**, Colizzi V, Pucillo LP, Poccia F. Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. **J Immunol.** **2002;168:1484-9.**

Mariani F, **Goletti D**, Ciaramella A, Martino A, Colizzi V, Fraziano M. Macrophage response to Mycobacterium tuberculosis during HIV infection: relationships between macrophage activation and apoptosis. **Curr Mol Med.** **2001; 2:209-16.**

Andreoni M, **Goletti D**, Pezzotti P, Pozzetto A, Monini P, Sarmati L, Farchi F, Tisone G, Piazza A, Pisani F, Angelico M, Leone P, Citterio F, Ensoli B, Rezza G. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. **J Infect.** **2001;43:195-9.**

Girardi E, **Goletti D**, Antonucci G, Ippolito G. Tuberculosis and HIV: a deadly interaction. **J Biol Regul Homeost Agents.** **2001 Jul-Sep;15:218-23.**

Monini P, Sirianni MC, Franco M, Vincenzi L, Topino S, **Goletti D**, Leone P, Leone P, Chiozzini C, Nicastri E, Andreoni M, Borduagni O, Sgadari C, Rezza G, Sturzl M, Ensoli B. Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. **Clin Infect Dis.** **2001;33:1782-5.**

Petrosillo N, Pellicelli AM, Cicalini S, Conte A, **Goletti D**, Palmieri F. Endocarditis caused by Aspergillus species in injection drug users. **Clin Infect Dis.** **2001;33:e97-9.**

Cafaro A, Titti F, Fracasso C, Mayrella MT, Baroncelli S, Caputo A, **Goletti D**, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaf P, Butto S, Verani P, Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). **Vaccine.** **2001;19:2862-77.**

Cafaro, A. Caputo, C. Fracasso, M.T. Mayrella, **D. Goletti**, S. Baroncelli, M. Pace, L. Sernicola, M.L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, B. Ensoli. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. **Nat Med** **5:643-50, 1999.**

Monini P, Colombini S, Stürzl M, **Goletti D**, Cafaro A, Sgadari C, Buttò S, Franco M, Leone P, Fais S, Leone P, Melucci-Vigo G, Chiozzini C, Carlini F, Ascherl G, Cornali E, Zietz C, Ramazzotti E, Ensoli F, Andreoni M, Pezzotti P, Rezza G, Yarchoan R, Gallo RC, Ensoli B. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. **Blood.** **1999 Jun 15;93(12):4044-58.**

Monini P, Carlini F, Stürzl M, Rimessi P, Superti F, Franco M, Melucci-Vigo G, Cafaro A, **Goletti D**, Sgadari C, Butto' S, Leone P, Chiozzini C, Barresi C, Tinari A, Bonaccorsi A, Capobianchi MR, Giuliani M, di Carlo A, Andreoni M, Rezza G, Ensoli B. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. **J Virol.** **1999 May;73(5):4029-41.**

**Goletti D**, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines. **J Infect Dis.** **1998 May;177(5):1332-8.**

Ostrowski MA, Stanley SK, Justement JS, Gantt K, **Goletti D**, Fauci AS. Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. **AIDS Res Hum Reoviruses.** **1997 Apr 10;13(6):473-80.**

Kinter AL, Ostrowski M, **Goletti D**, Oliva A, Weissman D, Gantt K, Hardy E, Jackson R, Ehler L, Fauci AS. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous

beta-chemokines and the viral inductive effects of other endogenous cytokines. **Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14076-81.**

**Goletti D**, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. **J Immunol. 1996 Aug 1;157(3):1271-8.**

**Goletti D**, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. **J Immunol. 1996 May 1;156(9):3501-8.**

Biswas P, Smith CA, **Goletti D**, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. **Immunity. 1995 Jun;2(6):587-96.**

**Goletti D**, Kinter AL, Biswas P, Bende SM, Poli G, Fauci AS. Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. **J Virol. 1995 Apr;69(4):2540-6.**

Cauda R, **Goletti D**, Lucia MB, Tumbarello M, Rumi C, Orengo AM, Moretta A. Analysis of natural killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions. **Clin Immunol Immunopathol. 1994 Mar;70(3):198-205.**

Burastero SE, Lo Pinto G, **Goletti D**, Cutolo M, Burlando L, Falagiani P. Rheumatoid arthritis with monoclonal IgE rheumatoid factor. **J Rheumatol. 1993 Mar;20(3):489-94.**

**Roma, July 6<sup>th</sup>, 2020**

I authorize the treatment of personal data based on the article 13 GDPR (UE 2016/679).

